[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fe0N1Ijg7P0rUiU011T7RwxRo6SNkViBbTEI2Ui1ioVA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":85,"rows":92},"Oregon Health and Science University",[4],684,false,133,14,6762265,43,471,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Parkinson's Disease",23,{"name":18,"count":19},"Obesity",22,{"name":21,"count":22},"Multiple Sclerosis",20,{"name":24,"count":25},"Contraception",18,{"name":27,"count":28},"Pain",15,{"name":30,"count":31},"Type 1 Diabetes",12,{"name":33,"count":34},"Depression",11,{"name":36,"count":34},"Parkinson Disease",[38,43,48,53,58,63,68,72,77,81],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03388788","Body Weight, Sleep, and Heart Health","2024-09-30","Positron Emission Tomography (PET) scanning of cardiac function at 3 time points across the 24 hour circadian cycle",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05543642","The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","2025-04-01","Hepatitis A vaccine",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT02968212","Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)","2025-08-29","Clofazimine",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05859490","Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination","2025-11-01","17D",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05591027","Safety and Target Engagement of Centella Asiatica in Cognitive Impairment","2025-11-30","Centella asiatica product",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03880656","BM-MNCs for Lower Extremity Compartment Syndrome Injury","2025-12","Intramuscular administration of autologous BM-MNCs",{"nctId":69,"briefTitle":70,"date":66,"intervention":71},"NCT06121466","Effect of Abdominal Wall Injections on Abdominal Pain","Abdominal wall injections with lidocaine 2%",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04921943","Hypertonic Saline for MAC","2025-12-31","Hypertonic saline",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT06206044","Evaluation of the Typical Spinal Block During Cesarean Delivery","Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine",{"nctId":82,"briefTitle":83,"date":75,"intervention":84},"NCT04281979","Effects of a Specific Substance in Smokers","Study Agent",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,135,175,204,229,247,265,283,312,330,353,371,398,423,449,473,497,522,540,561,586,626,648,677,695,713,735,764,782,807,827,850,873,898,916,941,963,986,1010,1031,1060,1078,1103,1121,1171,1209,1231,1255,1280,1306,1334,1352,1378,1396,1420,1446,1464,1488,1513,1539,1566,1584,1609,1627,1651,1669,1693,1718,1736,1760,1787,1805,1829,1855,1873,1898,1916,1941,1967,1993,2011,2029,2054,2081,2110,2128,2152,2177,2195,2220,2245,2263,2288,2306,2332,2350,2373,2398,2421,2448,2466,2492,2520,2538,2571,2589,2607,2625,2648,2672,2690,2715,2741,2766,2792,2810,2835,2867,2897,2923,2948,2966,2991,3009,3033,3068,3097,3127,3152,3170,3193,3218,3241,3266,3284,3306,3330,3354,3380,3404,3426,3452,3476,3498,3526,3549,3572,3599,3622,3648,3666,3684,3702,3726,3753,3775,3798,3824,3850,3875,3897,3921,3945,3969,3993,4020,4044,4069,4092,4118,4141,4159,4177,4200,4223,4246,4270,4292,4317,4335,4365,4383,4401,4419,4455,4477,4500,4526,4555,4582,4608,4626,4644,4668,4686,4710,4737,4755,4776,4840,4887,4915,4947,4977,5008,5030,5061,5086,5119,5147,5174,5195,5218,5242,5260,5278,5305,5323,5341,5364,5391,5409,5427,5445,5468,5490,5514,5532,5557,5587,5605,5623,5647,5665,5687,5710,5732,5755,5778,5800,5823,5841,5862,5880,5898,5916,5940,5967,5993,6011,6034,6059,6086,6104,6122,6140,6158,6181,6199,6220,6242,6266,6284,6307,6332,6350,6368,6393,6417],{"intervention":94,"totalTrials":95,"cells":96},"Ulipristal acetate",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":133},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":132,"soonestReadout":113},[108,120],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT05674513","Disparities in Emergency Contraceptive Metabolism Dictate Efficacy","RECRUITING",[90],"2026-12-31","2027-12-31","2023-01-09",140,[118],"Contraceptive Usage",[94],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT02577601","Impact of Combined Hormonal Contraceptives on UPA","COMPLETED",[90],"2017-06-17","2015-09-08",36,[24],[130,131],"Ulipristal Acetate","Levonorgestrel (LNG)\u002FEthinyl estradiol birth control pill",1,{"trials":134,"activeCount":99},[],{"intervention":136,"totalTrials":95,"cells":137},"Sevoflurane",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":173},{"trials":139,"activeCount":99},[],{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":132,"soonestReadout":152},[148,162],{"nctId":149,"briefTitle":150,"status":111,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":160},"NCT06036095","Total Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study",[90],"2027-03-15","2023-08-14",260,[156,157,158,159],"Neurocognitive Disorders","Anesthesia","Post-operative Delirium","Post-operative Cognitive Dysfunction",[136,161],"Propofol",{"nctId":163,"briefTitle":164,"status":123,"phases":165,"primaryCompletion":166,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT01048658","Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures",[90],"2010-12","2011-08","2009-09",160,[171,157],"Blood Loss",[136],{"trials":174,"activeCount":99},[],{"intervention":161,"totalTrials":95,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":196,"NA":202},{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":99},[],{"trials":182,"activeCount":99},[],{"trials":184,"activeCount":99},[185],{"nctId":186,"briefTitle":187,"status":123,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT01604785","Low-dose Propofol for Pediatric Migraine",[88,89],"2016-08","2012-11",74,[193],"Migraine Headache",[161,195],"Standard Treatment",{"trials":197,"activeCount":132,"soonestReadout":152},[198],{"nctId":149,"briefTitle":150,"status":111,"phases":199,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":200,"interventions":201},[90],[156,157,158,159],[136,161],{"trials":203,"activeCount":99},[],{"intervention":76,"totalTrials":132,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":227},{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":132,"soonestReadout":75},[216],{"nctId":73,"briefTitle":74,"status":111,"phases":217,"primaryCompletion":75,"completion":75,"start":218,"enrollment":219,"conditions":220,"interventions":223},[90],"2021-05-18",50,[221,222],"Nontuberculous Mycobacterial Lung Disease","Nontuberculous Mycobacterium Infection",[76,224,225,226],"Azithromycin","Ethambutol","Rifampin",{"trials":228,"activeCount":99},[],{"intervention":224,"totalTrials":132,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":132,"soonestReadout":75},[241],{"nctId":73,"briefTitle":74,"status":111,"phases":242,"primaryCompletion":75,"completion":75,"start":218,"enrollment":219,"conditions":243,"interventions":244},[90],[221,222],[76,224,225,226],{"trials":246,"activeCount":99},[],{"intervention":225,"totalTrials":132,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":263},{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":132,"soonestReadout":75},[259],{"nctId":73,"briefTitle":74,"status":111,"phases":260,"primaryCompletion":75,"completion":75,"start":218,"enrollment":219,"conditions":261,"interventions":262},[90],[221,222],[76,224,225,226],{"trials":264,"activeCount":99},[],{"intervention":226,"totalTrials":132,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":281},{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":99},[],{"trials":274,"activeCount":99},[],{"trials":276,"activeCount":132,"soonestReadout":75},[277],{"nctId":73,"briefTitle":74,"status":111,"phases":278,"primaryCompletion":75,"completion":75,"start":218,"enrollment":219,"conditions":279,"interventions":280},[90],[221,222],[76,224,225,226],{"trials":282,"activeCount":99},[],{"intervention":284,"totalTrials":132,"cells":285},"Chlorhexidine",{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":310},{"trials":287,"activeCount":99},[],{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":132,"soonestReadout":301},[296],{"nctId":297,"briefTitle":298,"status":299,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":308},"NCT06598514","Chlorhexidine Lavage for Recurrent Urinary Tract Infection","ACTIVE_NOT_RECRUITING",[90],"2026-04","2026-06","2024-12-23",136,[306,307],"Urinary Tract Infections","Recurrent Urinary Tract Infection",[284,309],"Sterile Water",{"trials":311,"activeCount":99},[],{"intervention":309,"totalTrials":132,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":328},{"trials":315,"activeCount":99},[],{"trials":317,"activeCount":99},[],{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":132,"soonestReadout":301},[324],{"nctId":297,"briefTitle":298,"status":299,"phases":325,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":326,"interventions":327},[90],[306,307],[284,309],{"trials":329,"activeCount":99},[],{"intervention":47,"totalTrials":132,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":351},{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":99},[],{"trials":341,"activeCount":132,"soonestReadout":46},[342],{"nctId":44,"briefTitle":45,"status":299,"phases":343,"primaryCompletion":46,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},[90],"2026-08","2022-10-11",129,[348],"Rheumatic Diseases",[47,350],"Diphtheria, pertussis, and tetanus booster vaccine",{"trials":352,"activeCount":99},[],{"intervention":350,"totalTrials":132,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":369},{"trials":356,"activeCount":99},[],{"trials":358,"activeCount":99},[],{"trials":360,"activeCount":99},[],{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":132,"soonestReadout":46},[365],{"nctId":44,"briefTitle":45,"status":299,"phases":366,"primaryCompletion":46,"completion":344,"start":345,"enrollment":346,"conditions":367,"interventions":368},[90],[348],[47,350],{"trials":370,"activeCount":99},[],{"intervention":372,"totalTrials":132,"cells":373},"Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.",{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":396},{"trials":375,"activeCount":99},[],{"trials":377,"activeCount":99},[],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":132,"soonestReadout":389},[384],{"nctId":385,"briefTitle":386,"status":387,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT07174401","Rocklatan Retinal Perfusion OCT Study","NOT_YET_RECRUITING",[90],"2026-12","2027-10","2026-01",30,[394],"Glaucoma",[372],{"trials":397,"activeCount":99},[],{"intervention":399,"totalTrials":132,"cells":400},"Prednisone 20 Mg",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":421},{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"trials":410,"activeCount":132,"soonestReadout":415},[411],{"nctId":412,"briefTitle":413,"status":387,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":420},"NCT04568837","Steroids After Spine Fusion Surgery",[90],"2026-10-06","2025-03-01",420,[419],"Spine Fusion",[399],{"trials":422,"activeCount":99},[],{"intervention":424,"totalTrials":132,"cells":425},"Iron-Dextran Complex Injection [InFed]",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":447},{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":132,"soonestReadout":440},[436],{"nctId":437,"briefTitle":438,"status":111,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":446},"NCT05292001","Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma",[90],"2026-05-31","2022-06-01",150,[444,445],"Acute Blood Loss Anemia","Fracture",[424],{"trials":448,"activeCount":99},[],{"intervention":450,"totalTrials":132,"cells":451},"Aficamten",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":471},{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":132,"soonestReadout":113},[462],{"nctId":463,"briefTitle":464,"status":111,"phases":465,"primaryCompletion":113,"completion":152,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NCT07600177","Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy",[90],"2026-05-05",40,[469],"Hypertrophic Cardiomyopathy (HCM)",[450],{"trials":472,"activeCount":99},[],{"intervention":474,"totalTrials":132,"cells":475},"Gonadotropin Releasing Hormone Antagonists Relugolix",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":495},{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":132,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":111,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":28,"conditions":492,"interventions":494},"NCT07111247","Insights in Endocervical Mucus Secretion",[90],"2027-08","2026-01-02",[493],"Cervical Mucus",[474],{"trials":496,"activeCount":99},[],{"intervention":498,"totalTrials":132,"cells":499},"Norethindrone 0.35 MG",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":520},{"trials":501,"activeCount":99},[],{"trials":503,"activeCount":99},[],{"trials":505,"activeCount":99},[],{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":132,"soonestReadout":389},[510],{"nctId":511,"briefTitle":512,"status":387,"phases":513,"primaryCompletion":389,"completion":389,"start":514,"enrollment":219,"conditions":515,"interventions":518},"NCT07293728","A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia",[90],"2026-07",[516,517],"Hypertension","Preeclampsia",[498,519],"Drospirenone",{"trials":521,"activeCount":99},[],{"intervention":519,"totalTrials":132,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":538},{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":132,"soonestReadout":389},[534],{"nctId":511,"briefTitle":512,"status":387,"phases":535,"primaryCompletion":389,"completion":389,"start":514,"enrollment":219,"conditions":536,"interventions":537},[90],[516,517],[498,519],{"trials":539,"activeCount":99},[],{"intervention":71,"totalTrials":132,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":559},{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":99},[],{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":132,"soonestReadout":66},[552],{"nctId":69,"briefTitle":70,"status":111,"phases":553,"primaryCompletion":66,"completion":66,"start":554,"enrollment":555,"conditions":556,"interventions":558},[90],"2023-01-01",45,[557],"Anterior Cutaneous Nerve Entrapment Syndrome",[71],{"trials":560,"activeCount":99},[],{"intervention":562,"totalTrials":132,"cells":563},"Amiodarone Hydrochloride",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":582,"NA":584},{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[],{"trials":571,"activeCount":132,"soonestReadout":114},[572],{"nctId":573,"briefTitle":574,"status":111,"phases":575,"primaryCompletion":114,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":581},"NCT06680869","Early Amiodarone in Shockable Cardiac Arrest",[89],"2028-01-31","2025-01-01",585,[580],"Cardiac Arrest",[562],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"intervention":587,"totalTrials":95,"cells":588},"Guselkumab",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":590,"activeCount":99},[],{"trials":592,"activeCount":99},[],{"trials":594,"activeCount":132,"soonestReadout":599},[595,609],{"nctId":596,"briefTitle":597,"status":111,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":608},"NCT06563323","Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)",[88],"2027-08-13","2025-02-01",17,[603,604,605,606,607],"Pyoderma Gangrenosum","Skin Diseases","Wound Heal","Pyoderma","Skin Ulcer",[587],{"nctId":610,"briefTitle":611,"status":123,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":28,"conditions":616,"interventions":618},"NCT03975153","Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)",[88],"2022-08-11","2024-03-22","2019-10-03",[617],"Pityriasis Rubra Pilaris",[619],"guselkumab",{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"intervention":57,"totalTrials":132,"cells":627},{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":632,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":132,"soonestReadout":56},[634],{"nctId":54,"briefTitle":55,"status":111,"phases":635,"primaryCompletion":56,"completion":75,"start":636,"enrollment":637,"conditions":638,"interventions":641},[87,88],"2023-08-01",35,[639,640],"Yellow Fever","Immunization; Infection",[57],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"intervention":649,"totalTrials":132,"cells":650},"Cefotetan",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":671,"PHASE4":673,"NA":675},{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":132,"soonestReadout":661},[657],{"nctId":658,"briefTitle":659,"status":387,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":668},"NCT07318584","Cefotetan Therapy for Escherichia Coli Infections",[88],"2028-02","2028-08","2026-03",84,[666,667],"E Coli Infection","ESBL Producing E.Coli",[649,669,670],"Carbapenems","Beta Lactam Antibiotics",{"trials":672,"activeCount":99},[],{"trials":674,"activeCount":99},[],{"trials":676,"activeCount":99},[],{"intervention":669,"totalTrials":132,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":132,"soonestReadout":661},[685],{"nctId":658,"briefTitle":659,"status":387,"phases":686,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":687,"interventions":688},[88],[666,667],[649,669,670],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":99},[],{"intervention":670,"totalTrials":132,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":698,"activeCount":99},[],{"trials":700,"activeCount":99},[],{"trials":702,"activeCount":132,"soonestReadout":661},[703],{"nctId":658,"briefTitle":659,"status":387,"phases":704,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":705,"interventions":706},[88],[666,667],[649,669,670],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"trials":712,"activeCount":99},[],{"intervention":52,"totalTrials":132,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":716,"activeCount":99},[],{"trials":718,"activeCount":99},[],{"trials":720,"activeCount":132,"soonestReadout":51},[721],{"nctId":49,"briefTitle":50,"status":299,"phases":722,"primaryCompletion":51,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":728},[88],"2026-10","2017-04-11",102,[727],"Mycobacterium Avium Complex",[52],{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"intervention":736,"totalTrials":132,"cells":737},"Finerenone",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":739,"activeCount":99},[],{"trials":741,"activeCount":99},[],{"trials":743,"activeCount":132,"soonestReadout":748},[744],{"nctId":745,"briefTitle":746,"status":387,"phases":747,"primaryCompletion":748,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":756},"NCT07594145","Precision T1D Platform - New Therapies for Cardio-Renal Complications",[88],"2029-12-31","2031-12-31","2026-09-01",57,[30,753,754,755],"T1D Diabetic Chronic Kidney Disease","T1D Heart Failure","Cardio-renal Vascular Function and Failure",[736,757],"Sotagliflozin",{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"intervention":757,"totalTrials":132,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":99},[],{"trials":771,"activeCount":132,"soonestReadout":748},[772],{"nctId":745,"briefTitle":746,"status":387,"phases":773,"primaryCompletion":748,"completion":749,"start":750,"enrollment":751,"conditions":774,"interventions":775},[88],[30,753,754,755],[736,757],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":99},[],{"trials":781,"activeCount":99},[],{"intervention":783,"totalTrials":132,"cells":784},"L-fucose",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":132,"soonestReadout":795},[791],{"nctId":792,"briefTitle":793,"status":111,"phases":794,"primaryCompletion":795,"completion":490,"start":466,"enrollment":796,"conditions":797,"interventions":800},"NCT07432490","A Phase II Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome",[88],"2027-07",16,[798,799],"Glut1 Deficiency","GLUT1DS1",[783],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[],{"intervention":67,"totalTrials":132,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":132,"soonestReadout":66},[813],{"nctId":64,"briefTitle":65,"status":299,"phases":814,"primaryCompletion":66,"completion":302,"start":815,"enrollment":25,"conditions":816,"interventions":818},[87],"2019-12-04",[817],"Compartment Syndrome Traumatic Lower Extremity",[67],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"intervention":62,"totalTrials":132,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":132,"soonestReadout":61},[833],{"nctId":59,"briefTitle":60,"status":111,"phases":834,"primaryCompletion":61,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":841},[87],"2026-03-31","2022-12-01",48,[839,840],"Mild Cognitive Impairment","Alzheimer's Disease",[62],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":99},[],{"trials":847,"activeCount":99},[],{"trials":849,"activeCount":99},[],{"intervention":851,"totalTrials":132,"cells":852},"Psilocybin",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":865,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":132,"soonestReadout":113},[857],{"nctId":858,"briefTitle":859,"status":387,"phases":860,"primaryCompletion":113,"completion":113,"start":861,"enrollment":28,"conditions":862,"interventions":864},"NCT06988319","Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study",[87],"2026-01-01",[863],"Chronic Pelvic Pain",[851],{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[],{"trials":870,"activeCount":99},[],{"trials":872,"activeCount":99},[],{"intervention":874,"totalTrials":132,"cells":875},"DMPA",{"EARLY_PHASE1":876,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":877,"activeCount":132,"soonestReadout":882},[878],{"nctId":879,"briefTitle":880,"status":111,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT05760144","Endometrial Biopsy in Progestin Contraceptive Users",[86],"2026-11","2023-07-01",52,[24],[874,887],"Etonogestrel implant",{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"intervention":887,"totalTrials":132,"cells":899},{"EARLY_PHASE1":900,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":901,"activeCount":132,"soonestReadout":882},[902],{"nctId":879,"briefTitle":880,"status":111,"phases":903,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":904,"interventions":905},[86],[24],[874,887],{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"intervention":917,"totalTrials":132,"cells":918},"Ferric derisomaltose",{"EARLY_PHASE1":919,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":920,"activeCount":132,"soonestReadout":925},[921],{"nctId":922,"briefTitle":923,"status":111,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},"NCT05763043","Monoferric for Prenatal Iron Deficiency",[86],"2028-10","2024-01-18",80,[929],"Obstetric Labor Complications",[917],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"intervention":42,"totalTrials":132,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":953},{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":132,"soonestReadout":41},[955],{"nctId":39,"briefTitle":40,"status":299,"phases":956,"primaryCompletion":41,"completion":957,"start":958,"enrollment":601,"conditions":959,"interventions":962},[],"2026-06-30","2018-05-01",[960,961,18],"Cardiovascular Risk Factor","Circadian Dysregulation",[42],{"intervention":964,"totalTrials":132,"cells":965},"OCT-guided laser phototherapeutic keratectomy",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":976},{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":99},[],{"trials":975,"activeCount":99},[],{"trials":977,"activeCount":132,"soonestReadout":389},[978],{"nctId":979,"briefTitle":980,"status":111,"phases":981,"primaryCompletion":389,"completion":389,"start":982,"enrollment":927,"conditions":983,"interventions":985},"NCT01243931","Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy",[91],"2011-06",[984],"Corneal Opacity",[964],{"intervention":80,"totalTrials":132,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[],{"trials":993,"activeCount":99},[],{"trials":995,"activeCount":99},[],{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":132,"soonestReadout":75},[1000],{"nctId":78,"briefTitle":79,"status":1001,"phases":1002,"primaryCompletion":75,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1009},"ENROLLING_BY_INVITATION",[],"2026-01-31","2024-06-10",250,[1007,1008],"Cesarean Section","Anesthesia, Obstetric",[80],{"intervention":84,"totalTrials":132,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1022},{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":132,"soonestReadout":75},[1024],{"nctId":82,"briefTitle":83,"status":111,"phases":1025,"primaryCompletion":75,"completion":75,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1030},[91],"2020-02-25",60,[1029],"Smoking",[84],{"intervention":1032,"totalTrials":132,"cells":1033},"Levonorgestrel Intrauterine System",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":99},[],{"trials":1045,"activeCount":132,"soonestReadout":1050},[1046],{"nctId":1047,"briefTitle":1048,"status":111,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1058},"NCT05916469","Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study",[],"2028-12","2029-06","2025-09-24",300,[1055,1056,1057],"Heavy Menstrual Bleeding","Bleeding Disorder","Von Willebrand Diseases",[1032,1059],"Norethindrone Acetate",{"intervention":1059,"totalTrials":132,"cells":1061},{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1072},{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":132,"soonestReadout":1050},[1074],{"nctId":1047,"briefTitle":1048,"status":111,"phases":1075,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":1053,"conditions":1076,"interventions":1077},[],[1055,1056,1057],[1032,1059],{"intervention":1079,"totalTrials":132,"cells":1080},"Menstrual disc with EMLA cream",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":132,"soonestReadout":301},[1093],{"nctId":1094,"briefTitle":1095,"status":111,"phases":1096,"primaryCompletion":301,"completion":301,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1101},"NCT06891794","Use of Cervical Cap and Menstrual Disc for Application of Topical Anesthetic Prior to IUD Insertion",[91],"2025-08-04",24,[1100],"IUD",[1079,1102],"Cervical cap with EMLA cream",{"intervention":1102,"totalTrials":132,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":132,"soonestReadout":301},[1117],{"nctId":1094,"briefTitle":1095,"status":111,"phases":1118,"primaryCompletion":301,"completion":301,"start":1097,"enrollment":1098,"conditions":1119,"interventions":1120},[91],[1100],[1079,1102],{"intervention":1122,"totalTrials":1123,"cells":1124},"Tamoxifen",3,{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1133,"NA":1169},{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":99},[1135,1145,1157],{"nctId":1136,"briefTitle":1137,"status":123,"phases":1138,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1144},"NCT02070692","Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users",[90],"2015-12","2014-02",56,[1143],"Menstruation Disturbances",[1122],{"nctId":1146,"briefTitle":1147,"status":123,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1156},"NCT02824224","Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)",[90],"2018-01-08","2016-09-06",42,[1153,1154,1155],"Menorrhagia","Metrorrhagia","Medicated Intrauterine Devices",[1122],{"nctId":1158,"briefTitle":1159,"status":123,"phases":1160,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1168},"NCT02903121","Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users",[90],"2019-06-05","2017-01-20",109,[1165,1166,1167],"Bleeding","Implants","Breakthrough Bleeding",[1122,1122],{"trials":1170,"activeCount":99},[],{"intervention":1172,"totalTrials":95,"cells":1173},"Sugammadex",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1207},{"trials":1175,"activeCount":99},[],{"trials":1177,"activeCount":99},[],{"trials":1179,"activeCount":99},[],{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":99},[1184,1196],{"nctId":1185,"briefTitle":1186,"status":123,"phases":1187,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1194},"NCT02861131","The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications",[90],"2018-04-30","2017-01-24",200,[1192,1193],"Postoperative Complications","Neuromuscular Blockade",[1172,1195],"Neostigmine",{"nctId":1197,"briefTitle":1198,"status":123,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1206},"NCT04546672","Sugammadex To IMprove Bowel Function",[90],"2023-06-14","2023-08-13","2021-03-16",120,[1205,1192,1193],"Bowel Dysfunction",[1172,1195],{"trials":1208,"activeCount":99},[],{"intervention":1195,"totalTrials":95,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1229},{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[],{"trials":1220,"activeCount":99},[1221,1225],{"nctId":1185,"briefTitle":1186,"status":123,"phases":1222,"primaryCompletion":1188,"completion":1188,"start":1189,"enrollment":1190,"conditions":1223,"interventions":1224},[90],[1192,1193],[1172,1195],{"nctId":1197,"briefTitle":1198,"status":123,"phases":1226,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":1203,"conditions":1227,"interventions":1228},[90],[1205,1192,1193],[1172,1195],{"trials":1230,"activeCount":99},[],{"intervention":1232,"totalTrials":132,"cells":1233},"Botox",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1253},{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":99},[],{"trials":1241,"activeCount":99},[],{"trials":1243,"activeCount":99},[1244],{"nctId":1245,"briefTitle":1246,"status":123,"phases":1247,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":219,"conditions":1250,"interventions":1252},"NCT00856999","Botox Cosmetic and the Young Patient With Glabellar Furrows",[90],"2010-11-17","2005-02-08",[1251],"Glabellar Furrows",[1232],{"trials":1254,"activeCount":99},[],{"intervention":1256,"totalTrials":132,"cells":1257},"Varied albuterol dose response",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1278},{"trials":1259,"activeCount":99},[],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[],{"trials":1267,"activeCount":99},[1268],{"nctId":1269,"briefTitle":1270,"status":123,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":9,"conditions":1274,"interventions":1277},"NCT02447250","Preterm Infant Inhaled Albuterol Dosing",[90],"2014-12-30","2013-10-24",[1275,1276],"Bronchopulmonary Dysplasia","Very Low Birth Weight",[1256],{"trials":1279,"activeCount":99},[],{"intervention":1281,"totalTrials":132,"cells":1282},"exenatide",{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1291,"NA":1304},{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[],{"trials":1292,"activeCount":99},[1293],{"nctId":1294,"briefTitle":1295,"status":123,"phases":1296,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1303},"NCT00667732","How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics",[90],"2009-10","2010-04","2007-03",41,[1302],"Type 2 Diabetes",[1281],{"trials":1305,"activeCount":99},[],{"intervention":1307,"totalTrials":132,"cells":1308},"Low Dose Enoxaparin",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1332},{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[],{"trials":1314,"activeCount":99},[],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[1319],{"nctId":1320,"briefTitle":1321,"status":1322,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1330},"NCT03805672","Below Knee DVT Study","TERMINATED",[90],"2015-07","2014-09",4,[1328,1329],"Deep Vein Thrombosis (DVT)","Blood Clots",[1307,1331],"High Dose Enoxaparin",{"trials":1333,"activeCount":99},[],{"intervention":1331,"totalTrials":132,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1350},{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[1346],{"nctId":1320,"briefTitle":1321,"status":1322,"phases":1347,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1348,"interventions":1349},[90],[1328,1329],[1307,1331],{"trials":1351,"activeCount":99},[],{"intervention":1353,"totalTrials":132,"cells":1354},"ECx1",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1376},{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[1365],{"nctId":1366,"briefTitle":1367,"status":123,"phases":1368,"primaryCompletion":1324,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1374},"NCT02408692","Emergency Contraception and Body Weight: Pilot Study",[90],"2015-08","2015-02",10,[24,1373],"Body Weight",[1353,1375],"ECx2",{"trials":1377,"activeCount":99},[],{"intervention":1375,"totalTrials":132,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1394},{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[1390],{"nctId":1366,"briefTitle":1367,"status":123,"phases":1391,"primaryCompletion":1324,"completion":1369,"start":1370,"enrollment":1371,"conditions":1392,"interventions":1393},[90],[24,1373],[1353,1375],{"trials":1395,"activeCount":99},[],{"intervention":1397,"totalTrials":132,"cells":1398},"Lidoderm 5 % Topical Patch",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1418},{"trials":1400,"activeCount":99},[],{"trials":1402,"activeCount":99},[],{"trials":1404,"activeCount":99},[],{"trials":1406,"activeCount":99},[],{"trials":1408,"activeCount":99},[1409],{"nctId":1410,"briefTitle":1411,"status":123,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":219,"conditions":1415,"interventions":1417},"NCT03500211","Post-Op Lidocaine Patch",[90],"2019-03-01","2018-03-13",[1416],"Pain, Postoperative",[1397],{"trials":1419,"activeCount":99},[],{"intervention":1421,"totalTrials":132,"cells":1422},"Levonorgestrel-based emergency contraception 1.5 mg",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1444},{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[1433],{"nctId":1434,"briefTitle":1435,"status":123,"phases":1436,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1442},"NCT02863445","Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG",[90],"2021-01-16","2021-08-16","2017-07-06",70,[18],[1421,1443],"Levonorgestrel-based emergency contraception 3.0mg",{"trials":1445,"activeCount":99},[],{"intervention":1443,"totalTrials":132,"cells":1447},{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1454,"PHASE4":1456,"NA":1462},{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":99},[1458],{"nctId":1434,"briefTitle":1435,"status":123,"phases":1459,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":1440,"conditions":1460,"interventions":1461},[90],[18],[1421,1443],{"trials":1463,"activeCount":99},[],{"intervention":1465,"totalTrials":132,"cells":1466},"Long Acting Reversible Contraception",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1486},{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[1477],{"nctId":1478,"briefTitle":1479,"status":1322,"phases":1480,"primaryCompletion":1481,"completion":1482,"start":1483,"enrollment":1123,"conditions":1484,"interventions":1485},"NCT02735551","LARC Forward Contraceptive Counseling at MHCC",[90],"2017-03-13","2017-03-31","2016-04",[24],[1465],{"trials":1487,"activeCount":99},[],{"intervention":1489,"totalTrials":132,"cells":1490},"Oxycodone 10mg",{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1511},{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":99},[],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[1501],{"nctId":1502,"briefTitle":1503,"status":123,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":1507,"conditions":1508,"interventions":1510},"NCT03139240","Opioid Analgesia for MAB",[90],"2018-05-31","2017-05-01",172,[1509,27],"MAB",[1489],{"trials":1512,"activeCount":99},[],{"intervention":1514,"totalTrials":132,"cells":1515},"Elemental calcium",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1537},{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[1526],{"nctId":1527,"briefTitle":1528,"status":123,"phases":1529,"primaryCompletion":1530,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1536},"NCT00228033","Effectiveness of Supplemental Calcium in Preventing Postpartum Depression",[90],"2005-12","2007-08","2002-04",238,[33,1535],"Depression, Postpartum",[1514],{"trials":1538,"activeCount":99},[],{"intervention":1540,"totalTrials":132,"cells":1541},"Golytely",{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1548,"PHASE4":1550,"NA":1564},{"trials":1543,"activeCount":99},[],{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[1552],{"nctId":1553,"briefTitle":1554,"status":1555,"phases":1556,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":1560,"interventions":1562},"NCT00889655","A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely","UNKNOWN",[90],"2010-05","2009-05",432,[1561],"Colonoscopy",[1540,1563],"MiraLax",{"trials":1565,"activeCount":99},[],{"intervention":1563,"totalTrials":132,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1582},{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[1578],{"nctId":1553,"briefTitle":1554,"status":1555,"phases":1579,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":1580,"interventions":1581},[90],[1561],[1540,1563],{"trials":1583,"activeCount":99},[],{"intervention":1585,"totalTrials":132,"cells":1586},"Magnesium sulfate 4g loading dose, 1g\u002Fhr",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1607},{"trials":1588,"activeCount":99},[],{"trials":1590,"activeCount":99},[],{"trials":1592,"activeCount":99},[],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[1597],{"nctId":1598,"briefTitle":1599,"status":123,"phases":1600,"primaryCompletion":1601,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1605},"NCT02835339","Magnesium Sulfate in Obese Preeclamptics",[90],"2019-06-30","2016-07-12",66,[517],[1585,1606],"Magnesium sulfate 6g loading dose, 2g\u002Fhr",{"trials":1608,"activeCount":99},[],{"intervention":1606,"totalTrials":132,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1625},{"trials":1612,"activeCount":99},[],{"trials":1614,"activeCount":99},[],{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[1621],{"nctId":1598,"briefTitle":1599,"status":123,"phases":1622,"primaryCompletion":1601,"completion":1601,"start":1602,"enrollment":1603,"conditions":1623,"interventions":1624},[90],[517],[1585,1606],{"trials":1626,"activeCount":99},[],{"intervention":1628,"totalTrials":132,"cells":1629},"escitalopram and sertraline",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1638,"NA":1649},{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[1640],{"nctId":1641,"briefTitle":1642,"status":123,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":467,"conditions":1646,"interventions":1648},"NCT00234312","Medications for the Treatment of Dysthymic Disorder and Double Depression",[90],"2006-10","2005-09",[33,1647],"Dysthymia",[1628],{"trials":1650,"activeCount":99},[],{"intervention":131,"totalTrials":132,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1661,"NA":1667},{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[1663],{"nctId":121,"briefTitle":122,"status":123,"phases":1664,"primaryCompletion":125,"completion":125,"start":126,"enrollment":127,"conditions":1665,"interventions":1666},[90],[24],[130,131],{"trials":1668,"activeCount":99},[],{"intervention":1670,"totalTrials":132,"cells":1671},"Curcumin",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1680,"NA":1691},{"trials":1673,"activeCount":99},[],{"trials":1675,"activeCount":99},[],{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[1682],{"nctId":1683,"briefTitle":1684,"status":123,"phases":1685,"primaryCompletion":1686,"completion":636,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1690},"NCT04205929","Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users",[90],"2022-11-05","2020-04-15",58,[1165,1166,1167],[1670],{"trials":1692,"activeCount":99},[],{"intervention":1694,"totalTrials":132,"cells":1695},"50mcg estradiol cream",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1716},{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[1706],{"nctId":1707,"briefTitle":1708,"status":123,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":219,"conditions":1712,"interventions":1714},"NCT03240081","Treating Postmenopausal Dyspareunia Where it Hurts",[90],"2019-11-21","2017-06-20",[1713],"Dyspareunia",[1694,1715],"100mcg estradiol cream",{"trials":1717,"activeCount":99},[],{"intervention":1715,"totalTrials":132,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1734},{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730],{"nctId":1707,"briefTitle":1708,"status":123,"phases":1731,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":219,"conditions":1732,"interventions":1733},[90],[1713],[1694,1715],{"trials":1735,"activeCount":99},[],{"intervention":1737,"totalTrials":132,"cells":1738},"Paracervical block technique with lidocaine",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1745,"PHASE4":1747,"NA":1758},{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[1749],{"nctId":1750,"briefTitle":1751,"status":123,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1757},"NCT01466491","Refining Paracervical Block Techniques for Pain Control in First Trimester Surgical Abortion",[90],"2013-05","2011-10",332,[27],[1737],{"trials":1759,"activeCount":99},[],{"intervention":1761,"totalTrials":132,"cells":1762},"Estrogen and Progesterone Replacement",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1769,"PHASE4":1771,"NA":1785},{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[1773],{"nctId":1774,"briefTitle":1775,"status":123,"phases":1776,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":1780,"interventions":1782},"NCT02969590","Regulation of Cervical Mucus Secretion",[90],"2017-08-23","2015-03-29",5,[1781,24],"Fertility",[1783,1761,1784],"Leuprolide acetate","Progestin",{"trials":1786,"activeCount":99},[],{"intervention":1784,"totalTrials":132,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1803},{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[],{"trials":1796,"activeCount":99},[],{"trials":1798,"activeCount":99},[1799],{"nctId":1774,"briefTitle":1775,"status":123,"phases":1800,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":1801,"interventions":1802},[90],[1781,24],[1783,1761,1784],{"trials":1804,"activeCount":99},[],{"intervention":1806,"totalTrials":132,"cells":1807},"Estradiol vaginal ring",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1827},{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[1818],{"nctId":1819,"briefTitle":1820,"status":123,"phases":1821,"primaryCompletion":1822,"completion":1822,"start":1823,"enrollment":467,"conditions":1824,"interventions":1826},"NCT03336437","Estrogen and the Urogenital Microbiome in GSM",[90],"2019-08-23","2018-02-01",[1825],"Menopause",[1806],{"trials":1828,"activeCount":99},[],{"intervention":1830,"totalTrials":132,"cells":1831},"Intracervical Lidocaine",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1853},{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[1842],{"nctId":1843,"briefTitle":1844,"status":123,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":191,"conditions":1848,"interventions":1851},"NCT01421641","Tenaculum Pain Control Study",[90],"2012-05","2011-09",[1849,1850],"Cervical Pain","Pelvic Pain",[1830,1852],"Topical Lidocaine Gel",{"trials":1854,"activeCount":99},[],{"intervention":1852,"totalTrials":132,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1863,"PHASE4":1865,"NA":1871},{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[],{"trials":1866,"activeCount":99},[1867],{"nctId":1843,"briefTitle":1844,"status":123,"phases":1868,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":191,"conditions":1869,"interventions":1870},[90],[1849,1850],[1830,1852],{"trials":1872,"activeCount":99},[],{"intervention":1874,"totalTrials":132,"cells":1875},"Strattera",{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1884,"NA":1896},{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"trials":1883,"activeCount":99},[],{"trials":1885,"activeCount":99},[1886],{"nctId":1887,"briefTitle":1888,"status":123,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":1892,"conditions":1893,"interventions":1894},"NCT01340885","Cognitive Decline in Non-demented PD",[90],"2013-01","2011-01",9,[15],[1874,1895],"Exelon",{"trials":1897,"activeCount":99},[],{"intervention":1895,"totalTrials":132,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1914},{"trials":1901,"activeCount":99},[],{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[1910],{"nctId":1887,"briefTitle":1888,"status":123,"phases":1911,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":1892,"conditions":1912,"interventions":1913},[90],[15],[1874,1895],{"trials":1915,"activeCount":99},[],{"intervention":1917,"totalTrials":132,"cells":1918},"GOCOVRI",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1927,"NA":1939},{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"trials":1928,"activeCount":99},[1929],{"nctId":1930,"briefTitle":1931,"status":123,"phases":1932,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":1937,"interventions":1938},"NCT04387773","Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease",[90],"2022-09-01","2022-09-30","2020-11-05",8,[36],[1917],{"trials":1940,"activeCount":99},[],{"intervention":1942,"totalTrials":132,"cells":1943},"Tranexamic acid",{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1950,"PHASE4":1952,"NA":1965},{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[],{"trials":1951,"activeCount":99},[],{"trials":1953,"activeCount":99},[1954],{"nctId":1955,"briefTitle":1956,"status":123,"phases":1957,"primaryCompletion":1958,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1964},"NCT06000423","Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects",[90],"2025-08-13","2025-08-14","2024-01-23",65,[1165,1963],"Contraceptive Device; Complications",[1942],{"trials":1966,"activeCount":99},[],{"intervention":1968,"totalTrials":132,"cells":1969},"All participants",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1991},{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[1980],{"nctId":1981,"briefTitle":1982,"status":123,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":168,"enrollment":1986,"conditions":1987,"interventions":1988},"NCT01170390","Oral Contraceptives and Body Mass Index",[90],"2011-03","2011-12",32,[1373,118],[1968,1989,1990],"Portia","Aviane",{"trials":1992,"activeCount":99},[],{"intervention":1989,"totalTrials":132,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2009},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[2005],{"nctId":1981,"briefTitle":1982,"status":123,"phases":2006,"primaryCompletion":1984,"completion":1985,"start":168,"enrollment":1986,"conditions":2007,"interventions":2008},[90],[1373,118],[1968,1989,1990],{"trials":2010,"activeCount":99},[],{"intervention":1990,"totalTrials":132,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2027},{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"trials":2020,"activeCount":99},[],{"trials":2022,"activeCount":99},[2023],{"nctId":1981,"briefTitle":1982,"status":123,"phases":2024,"primaryCompletion":1984,"completion":1985,"start":168,"enrollment":1986,"conditions":2025,"interventions":2026},[90],[1373,118],[1968,1989,1990],{"trials":2028,"activeCount":99},[],{"intervention":2030,"totalTrials":132,"cells":2031},"Atorvastatin 80 mg",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2052},{"trials":2033,"activeCount":99},[],{"trials":2035,"activeCount":99},[],{"trials":2037,"activeCount":99},[],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[2042],{"nctId":2043,"briefTitle":2044,"status":1555,"phases":2045,"primaryCompletion":2046,"start":2047,"enrollment":927,"conditions":2048,"interventions":2050},"NCT00736463","Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)",[90],"2012-01","2005-01",[2049],"HDL Cholesterol",[2051,2030],"Simvastatin",{"trials":2053,"activeCount":99},[],{"intervention":2055,"totalTrials":132,"cells":2056},"elbasvir-grazoprevir",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2079},{"trials":2058,"activeCount":99},[],{"trials":2060,"activeCount":99},[],{"trials":2062,"activeCount":99},[],{"trials":2064,"activeCount":99},[],{"trials":2066,"activeCount":99},[2067],{"nctId":2068,"briefTitle":2069,"status":123,"phases":2070,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":2073,"conditions":2074,"interventions":2078},"NCT03093415","Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care",[90],"2019-06-06","2017-05-30",100,[2075,2076,2077],"Hepatitis C","Substance Use Disorders","Substance Abuse, Intravenous",[2055],{"trials":2080,"activeCount":99},[],{"intervention":2082,"totalTrials":132,"cells":2083},"Midazolam",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2088,"PHASE3":2090,"PHASE4":2092,"NA":2108},{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[2094],{"nctId":2095,"briefTitle":2096,"status":123,"phases":2097,"primaryCompletion":2098,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2105},"NCT01830881","Evaluation of Oral Midazolam in First-trimester Surgical Abortions",[90],"2013-12","2014-01","2013-04",124,[27,2103,2104],"Anxiety","Nausea",[2082,2106,2107],"Ibuprofen","Lidocaine",{"trials":2109,"activeCount":99},[],{"intervention":2106,"totalTrials":132,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2120,"NA":2126},{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"trials":2121,"activeCount":99},[2122],{"nctId":2095,"briefTitle":2096,"status":123,"phases":2123,"primaryCompletion":2098,"completion":2099,"start":2100,"enrollment":2101,"conditions":2124,"interventions":2125},[90],[27,2103,2104],[2082,2106,2107],{"trials":2127,"activeCount":99},[],{"intervention":2129,"totalTrials":132,"cells":2130},"Nutropin AQ",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2150},{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[2141],{"nctId":2142,"briefTitle":2143,"status":123,"phases":2144,"primaryCompletion":2145,"completion":1557,"start":2047,"enrollment":601,"conditions":2146,"interventions":2149},"NCT00212758","A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood",[90],"2008-05",[2147,2148],"Kidney Failure, Chronic","Growth Hormone Deficiency",[2129],{"trials":2151,"activeCount":99},[],{"intervention":2153,"totalTrials":132,"cells":2154},"UPA-ECx1",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2163,"NA":2175},{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[2165],{"nctId":2166,"briefTitle":2167,"status":123,"phases":2168,"primaryCompletion":2169,"completion":2170,"start":2072,"enrollment":2171,"conditions":2172,"interventions":2173},"NCT02859337","Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA",[90],"2022-01-13","2023-11-15",64,[18,24],[2153,2174],"UPA-ECx2",{"trials":2176,"activeCount":99},[],{"intervention":2174,"totalTrials":132,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2193},{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"trials":2186,"activeCount":99},[],{"trials":2188,"activeCount":99},[2189],{"nctId":2166,"briefTitle":2167,"status":123,"phases":2190,"primaryCompletion":2169,"completion":2170,"start":2072,"enrollment":2171,"conditions":2191,"interventions":2192},[90],[18,24],[2153,2174],{"trials":2194,"activeCount":99},[],{"intervention":2196,"totalTrials":132,"cells":2197},"Saxagliptin",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2218},{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[2208],{"nctId":2209,"briefTitle":2210,"status":2211,"phases":2212,"primaryCompletion":2213,"completion":2214,"start":2046,"enrollment":28,"conditions":2215,"interventions":2217},"NCT01527747","Effects of DPP-4 Inhibition on Triglycerides","SUSPENDED",[90],"2024-11","2024-12",[1302,2216],"Hypertriglyceridemia",[2196],{"trials":2219,"activeCount":99},[],{"intervention":2221,"totalTrials":132,"cells":2222},"Gabapentin 250mg\u002F5mL NDC:59762-5025-01",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2243},{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[],{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[2233],{"nctId":2234,"briefTitle":2235,"status":123,"phases":2236,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":2239,"conditions":2240,"interventions":2241},"NCT01977937","Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin",[90],"2018-04","2013-11",55,[1416],[2221,2242],"Simple Syrup",{"trials":2244,"activeCount":99},[],{"intervention":2242,"totalTrials":132,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2261},{"trials":2248,"activeCount":99},[],{"trials":2250,"activeCount":99},[],{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"trials":2256,"activeCount":99},[2257],{"nctId":2234,"briefTitle":2235,"status":123,"phases":2258,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":2239,"conditions":2259,"interventions":2260},[90],[1416],[2221,2242],{"trials":2262,"activeCount":99},[],{"intervention":2264,"totalTrials":132,"cells":2265},"Teriparatide",{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2272,"PHASE4":2274,"NA":2286},{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[2276],{"nctId":2277,"briefTitle":2278,"status":123,"phases":2279,"primaryCompletion":1891,"completion":1891,"start":2280,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT00131469","Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta",[90],"2005-06",79,[2283],"Osteogenesis Imperfecta",[2264,2285],"Placebos",{"trials":2287,"activeCount":99},[],{"intervention":2285,"totalTrials":132,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2304},{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":99},[],{"trials":2297,"activeCount":99},[],{"trials":2299,"activeCount":99},[2300],{"nctId":2277,"briefTitle":2278,"status":123,"phases":2301,"primaryCompletion":1891,"completion":1891,"start":2280,"enrollment":2281,"conditions":2302,"interventions":2303},[90],[2283],[2264,2285],{"trials":2305,"activeCount":99},[],{"intervention":2307,"totalTrials":132,"cells":2308},"Genetically-guided treatment with FDA-approved psychotropic drugs",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2330},{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[],{"trials":2318,"activeCount":99},[2319],{"nctId":2320,"briefTitle":2321,"status":2322,"phases":2323,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":99,"conditions":2326,"interventions":2328},"NCT03907124","Clinical Utility of Pharmacogenomics of Psychotropic Medications","WITHDRAWN",[90],"2021-07-09","2019-06-03",[2327,27],"Psychiatric Disorders",[2307,2329],"Treatment as usual",{"trials":2331,"activeCount":99},[],{"intervention":2329,"totalTrials":132,"cells":2333},{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2340,"PHASE4":2342,"NA":2348},{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[],{"trials":2339,"activeCount":99},[],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[2344],{"nctId":2320,"briefTitle":2321,"status":2322,"phases":2345,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":99,"conditions":2346,"interventions":2347},[90],[2327,27],[2307,2329],{"trials":2349,"activeCount":99},[],{"intervention":2351,"totalTrials":132,"cells":2352},"Sterile Saline",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2371},{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[],{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[2363],{"nctId":2364,"briefTitle":2365,"status":123,"phases":2366,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1688,"conditions":2369,"interventions":2370},"NCT00613834","Intrauterine Lidocaine Infusion for Essure Sterilization Procedures",[90],"2008-06","2007-05",[27],[2107,2351],{"trials":2372,"activeCount":99},[],{"intervention":2374,"totalTrials":132,"cells":2375},"Levonorgestrel IUS",{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2382,"PHASE4":2384,"NA":2396},{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[2386],{"nctId":2387,"briefTitle":2388,"status":1322,"phases":2389,"primaryCompletion":2390,"completion":2391,"start":2392,"enrollment":2393,"conditions":2394,"interventions":2395},"NCT01594476","Early Postpartum Intrauterine Device (IUD) Placement",[90],"2014-04","2014-07","2012-03",201,[24],[2374],{"trials":2397,"activeCount":99},[],{"intervention":2399,"totalTrials":132,"cells":2400},"Nitrous oxide",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2407,"PHASE4":2409,"NA":2419},{"trials":2402,"activeCount":99},[],{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[2411],{"nctId":2412,"briefTitle":2413,"status":123,"phases":2414,"primaryCompletion":1754,"completion":1754,"start":2415,"enrollment":22,"conditions":2416,"interventions":2418},"NCT00967694","Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers",[90],"2009-08",[394,2417],"Sedation",[2399],{"trials":2420,"activeCount":99},[],{"intervention":2422,"totalTrials":132,"cells":2423},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2446},{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[2434],{"nctId":2435,"briefTitle":2436,"status":123,"phases":2437,"primaryCompletion":2438,"completion":2439,"start":1324,"enrollment":2440,"conditions":2441,"interventions":2444},"NCT01936857","Buprenorphine to Improve HIV Care Engagement and Outcomes",[90],"2019-03","2019-04",281,[2442,2443],"HIV","Substance Related Disorders",[2422,2445],"Methadone Maintenance Therapy",{"trials":2447,"activeCount":99},[],{"intervention":2445,"totalTrials":132,"cells":2449},{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2464},{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[2460],{"nctId":2435,"briefTitle":2436,"status":123,"phases":2461,"primaryCompletion":2438,"completion":2439,"start":1324,"enrollment":2440,"conditions":2462,"interventions":2463},[90],[2442,2443],[2422,2445],{"trials":2465,"activeCount":99},[],{"intervention":2467,"totalTrials":132,"cells":2468},"Fluocinonide",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2475,"PHASE4":2477,"NA":2490},{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[2479],{"nctId":2480,"briefTitle":2481,"status":123,"phases":2482,"primaryCompletion":2483,"completion":2484,"start":2485,"enrollment":2486,"conditions":2487,"interventions":2489},"NCT00819507","VANOS Cream and Skin Barrier Function",[90],"2010-01","2010-06-21","2009-01",25,[2488],"Atopic Dermatitis",[2467],{"trials":2491,"activeCount":99},[],{"intervention":2493,"totalTrials":132,"cells":2494},"Enoxaparin Sodium Injection 30 mg BID",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2518},{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[2505],{"nctId":2506,"briefTitle":2507,"status":1555,"phases":2508,"primaryCompletion":2509,"completion":2510,"start":1140,"enrollment":2511,"conditions":2512,"interventions":2516},"NCT02342444","Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)",[90],"2024-12-31","2025-03-31",606,[2513,2514,1328,2515],"Trauma","Surgery","Thromboembolic Events",[2493,2517],"Enoxaparin Sodium Injection 40 mg QD",{"trials":2519,"activeCount":99},[],{"intervention":2517,"totalTrials":132,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2536},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":99},[2532],{"nctId":2506,"briefTitle":2507,"status":1555,"phases":2533,"primaryCompletion":2509,"completion":2510,"start":1140,"enrollment":2511,"conditions":2534,"interventions":2535},[90],[2513,2514,1328,2515],[2493,2517],{"trials":2537,"activeCount":99},[],{"intervention":2539,"totalTrials":132,"cells":2540},"Prednisolone",{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2569},{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":99},[2551],{"nctId":2552,"briefTitle":2553,"status":1555,"phases":2554,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":2558,"conditions":2559,"interventions":2565},"NCT02373137","Descemet Endothelial Thickness Comparison Trial",[90],"2018-04-04","2023-05-30","2015-01-22",38,[2560,2561,2562,2563,2564],"Keratoplasty","Grafting, Corneal","Transplantation, Corneal","Transplantation, Cornea","Keratoplasty, Lamellar",[2539,2566,2567,2568],"Ofloxacin","Tropicamide","Phenylephrine",{"trials":2570,"activeCount":99},[],{"intervention":2566,"totalTrials":132,"cells":2572},{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2579,"PHASE4":2581,"NA":2587},{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"trials":2580,"activeCount":99},[],{"trials":2582,"activeCount":99},[2583],{"nctId":2552,"briefTitle":2553,"status":1555,"phases":2584,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":2558,"conditions":2585,"interventions":2586},[90],[2560,2561,2562,2563,2564],[2539,2566,2567,2568],{"trials":2588,"activeCount":99},[],{"intervention":2567,"totalTrials":132,"cells":2590},{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2597,"PHASE4":2599,"NA":2605},{"trials":2592,"activeCount":99},[],{"trials":2594,"activeCount":99},[],{"trials":2596,"activeCount":99},[],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[2601],{"nctId":2552,"briefTitle":2553,"status":1555,"phases":2602,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":2558,"conditions":2603,"interventions":2604},[90],[2560,2561,2562,2563,2564],[2539,2566,2567,2568],{"trials":2606,"activeCount":99},[],{"intervention":2568,"totalTrials":132,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2623},{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[],{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[2619],{"nctId":2552,"briefTitle":2553,"status":1555,"phases":2620,"primaryCompletion":2555,"completion":2556,"start":2557,"enrollment":2558,"conditions":2621,"interventions":2622},[90],[2560,2561,2562,2563,2564],[2539,2566,2567,2568],{"trials":2624,"activeCount":99},[],{"intervention":2626,"totalTrials":132,"cells":2627},"ethinyl estradiol \u002F levonorgestrel",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2636,"NA":2646},{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[],{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[],{"trials":2637,"activeCount":99},[2638],{"nctId":2639,"briefTitle":2640,"status":123,"phases":2641,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":1203,"conditions":2644,"interventions":2645},"NCT00662454","Oral Contraceptive Efficacy and Body Weight",[90],"2006-05","2006-01",[24,1373],[2626,2626],{"trials":2647,"activeCount":99},[],{"intervention":2649,"totalTrials":132,"cells":2650},"Cannabidiol Oil",{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2670},{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[2661],{"nctId":2662,"briefTitle":2663,"status":123,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":1892,"conditions":2667,"interventions":2668},"NCT04396730","Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction",[90],"2022-03-02","2020-04-08",[24],[2649,2669],"Combined oral contraceptive pill",{"trials":2671,"activeCount":99},[],{"intervention":2669,"totalTrials":132,"cells":2673},{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2680,"PHASE4":2682,"NA":2688},{"trials":2675,"activeCount":99},[],{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[2684],{"nctId":2662,"briefTitle":2663,"status":123,"phases":2685,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":1892,"conditions":2686,"interventions":2687},[90],[24],[2649,2669],{"trials":2689,"activeCount":99},[],{"intervention":2691,"totalTrials":132,"cells":2692},"Methamphetamine Hydrochloride",{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2697,"PHASE3":2699,"PHASE4":2701,"NA":2713},{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[],{"trials":2698,"activeCount":99},[],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[2703],{"nctId":2704,"briefTitle":2705,"status":123,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":2709,"conditions":2710,"interventions":2712},"NCT03973489","Effects of Genotype on Resting State Connectivity During Methamphetamine Administration",[90],"2023-03-31","2019-08-16",69,[2711],"Methamphetamine-dependence",[2691],{"trials":2714,"activeCount":99},[],{"intervention":2716,"totalTrials":132,"cells":2717},"Dronabinol 5mg Cap",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2724,"PHASE4":2726,"NA":2739},{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[2728],{"nctId":2729,"briefTitle":2730,"status":123,"phases":2731,"primaryCompletion":2732,"completion":2733,"start":2734,"enrollment":2735,"conditions":2736,"interventions":2738},"NCT03604341","Cannabinoids for Pain Control During Medical Abortion",[90],"2019-05-07","2019-05-28","2018-11-01",72,[2737,27],"Medical Abortion",[2716],{"trials":2740,"activeCount":99},[],{"intervention":2742,"totalTrials":132,"cells":2743},"Triamcinolone Acetonide",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2748,"PHASE3":2750,"PHASE4":2752,"NA":2764},{"trials":2745,"activeCount":99},[],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[],{"trials":2751,"activeCount":99},[],{"trials":2753,"activeCount":99},[2754],{"nctId":2755,"briefTitle":2756,"status":2322,"phases":2757,"primaryCompletion":2758,"completion":2758,"start":2759,"enrollment":99,"conditions":2760,"interventions":2763},"NCT02598869","Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema",[90],"2016-05-15","2015-11-30",[2761,2762],"Uveitis","Cystoid Macular Edema",[2742],{"trials":2765,"activeCount":99},[],{"intervention":2767,"totalTrials":132,"cells":2768},"Chloroprocaine Injection [Clorotekal]",{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2790},{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"trials":2778,"activeCount":99},[2779],{"nctId":2780,"briefTitle":2781,"status":2211,"phases":2782,"primaryCompletion":2783,"completion":75,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2788},"NCT03967288","Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery",[90],"2025-06-30","2019-10-24",27,[2787],"Anesthesia, Spinal",[2767,2789],"Bupivacaine Hydrochloride 0.75% Injection Solution",{"trials":2791,"activeCount":99},[],{"intervention":2789,"totalTrials":132,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2802,"NA":2808},{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[2804],{"nctId":2780,"briefTitle":2781,"status":2211,"phases":2805,"primaryCompletion":2783,"completion":75,"start":2784,"enrollment":2785,"conditions":2806,"interventions":2807},[90],[2787],[2767,2789],{"trials":2809,"activeCount":99},[],{"intervention":2811,"totalTrials":132,"cells":2812},"L-thyroxine",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2833},{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[2823],{"nctId":2824,"briefTitle":2825,"status":123,"phases":2826,"primaryCompletion":2827,"completion":2827,"start":2828,"enrollment":2829,"conditions":2830,"interventions":2832},"NCT00565864","Neurocognitive and Metabolic Effects of Mild Hypothyroidism",[90],"2013-08","2008-08",173,[2831],"Hypothyroidism",[2811],{"trials":2834,"activeCount":99},[],{"intervention":2836,"totalTrials":95,"cells":2837},"Methylphenidate",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2854,"PHASE4":2863,"NA":2865},{"trials":2839,"activeCount":99},[],{"trials":2841,"activeCount":99},[],{"trials":2843,"activeCount":99},[2844],{"nctId":2845,"briefTitle":2846,"status":123,"phases":2847,"primaryCompletion":2643,"completion":2848,"start":2849,"enrollment":2850,"conditions":2851,"interventions":2852},"NCT00359723","Methylphenidate and Parkinson's Disease",[88],"2006-03","2004-07",13,[15],[2853],"methylphenidate",{"trials":2855,"activeCount":99},[2856],{"nctId":2857,"briefTitle":2858,"status":123,"phases":2859,"primaryCompletion":1483,"completion":1483,"start":2860,"enrollment":1098,"conditions":2861,"interventions":2862},"NCT01896700","Methylphenidate to Improve Balance and Walking in MS",[88,89],"2013-07",[21],[2836],{"trials":2864,"activeCount":99},[],{"trials":2866,"activeCount":99},[],{"intervention":2868,"totalTrials":95,"cells":2869},"Ranibizumab",{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2876,"PHASE4":2893,"NA":2895},{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[],{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[2878,2886],{"nctId":2879,"briefTitle":2880,"status":123,"phases":2881,"primaryCompletion":2882,"completion":2882,"start":1644,"enrollment":132,"conditions":2883,"interventions":2885},"NCT00384449","Lucentis (Ranibizumab) for Eales' Disease",[88,89],"2009-04",[2884],"Eales' Disease",[2868],{"nctId":2887,"briefTitle":2888,"status":123,"phases":2889,"primaryCompletion":1298,"completion":1298,"start":2368,"enrollment":442,"conditions":2890,"interventions":2892},"NCT00469352","A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD",[89],[2891],"Macular Degeneration",[2868],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"intervention":2898,"totalTrials":132,"cells":2899},"Naltrexone Injectable Suspension",{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2906,"PHASE4":2919,"NA":2921},{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[],{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[2908],{"nctId":2909,"briefTitle":2910,"status":123,"phases":2911,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":2914,"conditions":2915,"interventions":2918},"NCT03275350","Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up",[88,89],"2019-11-08","2018-02-05",114,[2916,2917],"Opioid-use Disorder","Hiv",[2898],{"trials":2920,"activeCount":99},[],{"trials":2922,"activeCount":99},[],{"intervention":2924,"totalTrials":132,"cells":2925},"Whole blood transfusion",{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2944,"NA":2946},{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[2934],{"nctId":2935,"briefTitle":2936,"status":1555,"phases":2937,"primaryCompletion":2938,"completion":2938,"start":2939,"enrollment":2073,"conditions":2940,"interventions":2942},"NCT06184828","Pilot Study of Whole Blood Transfusion for Trauma Brain Injury (TBI)",[89],"2025-09-30","2024-08-01",[2941],"Traumatic Brain Injury",[2924,2943],"Blood components transfusion",{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[],{"intervention":2943,"totalTrials":132,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2962,"NA":2964},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[2958],{"nctId":2935,"briefTitle":2936,"status":1555,"phases":2959,"primaryCompletion":2938,"completion":2938,"start":2939,"enrollment":2073,"conditions":2960,"interventions":2961},[89],[2941],[2924,2943],{"trials":2963,"activeCount":99},[],{"trials":2965,"activeCount":99},[],{"intervention":2967,"totalTrials":132,"cells":2968},"Advate",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2987,"NA":2989},{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[2977],{"nctId":2978,"briefTitle":2979,"status":123,"phases":2980,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":796,"conditions":2983,"interventions":2986},"NCT02306694","Prospective Biomarkers of Bone Metabolism in Hemophilia A",[89],"2018-04-16","2014-12",[2984,2985],"Hemophilia","Bone Disease",[2967],{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"intervention":195,"totalTrials":132,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":2999,"PHASE4":3005,"NA":3007},{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[3001],{"nctId":186,"briefTitle":187,"status":123,"phases":3002,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":3003,"interventions":3004},[88,89],[193],[161,195],{"trials":3006,"activeCount":99},[],{"trials":3008,"activeCount":99},[],{"intervention":3010,"totalTrials":132,"cells":3011},"Memantine",{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3018,"PHASE4":3029,"NA":3031},{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"trials":3017,"activeCount":99},[],{"trials":3019,"activeCount":99},[3020],{"nctId":3021,"briefTitle":3022,"status":123,"phases":3023,"primaryCompletion":2485,"completion":2485,"start":3024,"enrollment":3025,"conditions":3026,"interventions":3028},"NCT00300716","Trial of Memantine for Cognitive Impairment in Multiple Sclerosis",[88,89],"2004-04",82,[21,3027],"Cognition Disorders",[3010],{"trials":3030,"activeCount":99},[],{"trials":3032,"activeCount":99},[],{"intervention":3034,"totalTrials":95,"cells":3035},"lipoic acid",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3050,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[3040],{"nctId":3041,"briefTitle":3042,"status":123,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":1891,"enrollment":3045,"conditions":3046,"interventions":3048},"NCT01294176","Lipoic Acid as a Treatment for Acute Optic Neuritis",[87],"2016-11",31,[3047],"Optic Neuritis",[3049],"Lipoic Acid",{"trials":3051,"activeCount":99},[3052],{"nctId":3053,"briefTitle":3054,"status":123,"phases":3055,"primaryCompletion":1890,"completion":1890,"start":3056,"enrollment":3057,"conditions":3058,"interventions":3061},"NCT00962429","Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy",[88],"2009-02",7,[3059,3060],"CIDP","Chronic Inflammatory Demyelinating Polyneuropathy",[3034],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"intervention":3069,"totalTrials":95,"cells":3070},"Apremilast",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3072,"activeCount":99},[],{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[3077,3084],{"nctId":3078,"briefTitle":3079,"status":1322,"phases":3080,"primaryCompletion":982,"completion":982,"start":3081,"enrollment":1123,"conditions":3082,"interventions":3083},"NCT00889421","Apremilast in the Treatment of Uveitis",[87,88],"2009-11",[2761],[3069],{"nctId":3085,"briefTitle":3086,"status":123,"phases":3087,"primaryCompletion":3088,"completion":3088,"start":1558,"enrollment":796,"conditions":3089,"interventions":3090},"NCT01393158","Apremilast for Atopic Dermatitis - A Pilot Study in Adults",[88],"2011-07",[2488],[3069],{"trials":3092,"activeCount":99},[],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"intervention":3098,"totalTrials":95,"cells":3099},"Apomorphine",{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3101,"activeCount":99},[],{"trials":3103,"activeCount":99},[],{"trials":3105,"activeCount":99},[3106,3113],{"nctId":3107,"briefTitle":3108,"status":2322,"phases":3109,"primaryCompletion":982,"completion":982,"start":3110,"enrollment":99,"conditions":3111,"interventions":3112},"NCT00758368","Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease",[88],"2009-03",[15],[3098],{"nctId":3114,"briefTitle":3115,"status":2322,"phases":3116,"primaryCompletion":2368,"completion":2368,"start":3117,"enrollment":99,"conditions":3118,"interventions":3119},"NCT00472355","Low Dose Apomorphine and Parkinsonism",[88],"2005-10",[15],[3120],"apomorphine",{"trials":3122,"activeCount":99},[],{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"intervention":3128,"totalTrials":132,"cells":3129},"combination ranibizumab + bromfenac",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3146,"PHASE4":3148,"NA":3150},{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[],{"trials":3135,"activeCount":99},[3136],{"nctId":3137,"briefTitle":3138,"status":123,"phases":3139,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":392,"conditions":3142,"interventions":3144},"NCT00805233","Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration",[88],"2010-09","2008-12",[3143],"Age-Related Macular Degeneration",[3128,3145],"ranibizumab injection alone",{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"intervention":3145,"totalTrials":132,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3155,"activeCount":99},[],{"trials":3157,"activeCount":99},[],{"trials":3159,"activeCount":99},[3160],{"nctId":3137,"briefTitle":3138,"status":123,"phases":3161,"primaryCompletion":3140,"completion":3140,"start":3141,"enrollment":392,"conditions":3162,"interventions":3163},[88],[3143],[3128,3145],{"trials":3165,"activeCount":99},[],{"trials":3167,"activeCount":99},[],{"trials":3169,"activeCount":99},[],{"intervention":3171,"totalTrials":132,"cells":3172},"Dalfampridine",{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[3179],{"nctId":3180,"briefTitle":3181,"status":123,"phases":3182,"primaryCompletion":3183,"completion":3183,"start":1847,"enrollment":1098,"conditions":3184,"interventions":3186},"NCT01444300","Dalfampridine for Imbalance in Multiple Sclerosis",[88],"2013-09",[21,3185],"Fatigue",[3171],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[],{"trials":3192,"activeCount":99},[],{"intervention":3194,"totalTrials":132,"cells":3195},"lipoic acid and omega-3 fatty acids",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3212,"PHASE4":3214,"NA":3216},{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[3202],{"nctId":3203,"briefTitle":3204,"status":123,"phases":3205,"primaryCompletion":3206,"completion":3206,"start":3207,"enrollment":3208,"conditions":3209,"interventions":3211},"NCT02133664","Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis",[87,88],"2016-05","2014-06",54,[21,3210],"Cognition",[3194],{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[],{"trials":3217,"activeCount":99},[],{"intervention":3219,"totalTrials":132,"cells":3220},"carbidopa",{"EARLY_PHASE1":3221,"PHASE1":3223,"PHASE2":3225,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[3227],{"nctId":3228,"briefTitle":3229,"status":123,"phases":3230,"primaryCompletion":3231,"completion":3232,"start":3110,"enrollment":9,"conditions":3233,"interventions":3234},"NCT01399905","High and Low Dose Carbidopa Treatment of Parkinson's Disease",[88],"2011-04","2011-05",[15],[3219],{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"intervention":3242,"totalTrials":132,"cells":3243},"pyridostigmine",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[3250],{"nctId":3251,"briefTitle":3252,"status":123,"phases":3253,"primaryCompletion":2367,"completion":2367,"start":3254,"enrollment":3255,"conditions":3256,"interventions":3258},"NCT00535587","Testing Mestinon and Exercise in Fibromyalgia",[88],"2002-09",178,[3257],"Fibromyalgia",[3242,3259],"Placibo",{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"intervention":3259,"totalTrials":132,"cells":3267},{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3278,"PHASE4":3280,"NA":3282},{"trials":3269,"activeCount":99},[],{"trials":3271,"activeCount":99},[],{"trials":3273,"activeCount":99},[3274],{"nctId":3251,"briefTitle":3252,"status":123,"phases":3275,"primaryCompletion":2367,"completion":2367,"start":3254,"enrollment":3255,"conditions":3276,"interventions":3277},[88],[3257],[3242,3259],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[],{"trials":3283,"activeCount":99},[],{"intervention":3285,"totalTrials":132,"cells":3286},"Adalimumab",{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3300,"PHASE4":3302,"NA":3304},{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[3293],{"nctId":3294,"briefTitle":3295,"status":123,"phases":3296,"primaryCompletion":3140,"completion":3140,"start":3297,"enrollment":3045,"conditions":3298,"interventions":3299},"NCT00525902","Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis",[88],"2008-01",[2761],[3285],{"trials":3301,"activeCount":99},[],{"trials":3303,"activeCount":99},[],{"trials":3305,"activeCount":99},[],{"intervention":3307,"totalTrials":132,"cells":3308},"Prothrombin Complex Concentrate, Human",{"EARLY_PHASE1":3309,"PHASE1":3311,"PHASE2":3313,"PHASE3":3324,"PHASE4":3326,"NA":3328},{"trials":3310,"activeCount":99},[],{"trials":3312,"activeCount":99},[],{"trials":3314,"activeCount":99},[3315],{"nctId":3316,"briefTitle":3317,"status":1555,"phases":3318,"primaryCompletion":2509,"completion":2510,"start":3319,"enrollment":3320,"conditions":3321,"interventions":3323},"NCT04019015","Prehospital Kcentra for Hemorrhagic Shock",[88],"2021-03-15",166,[3322],"Trauma Injury",[3307],{"trials":3325,"activeCount":99},[],{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[],{"intervention":3331,"totalTrials":132,"cells":3332},"Vitamin D3",{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3337,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[3339],{"nctId":3340,"briefTitle":3341,"status":123,"phases":3342,"primaryCompletion":3343,"completion":3343,"start":3344,"enrollment":22,"conditions":3345,"interventions":3347},"NCT01366885","Vitamin D to Prevent Autism in Newborn Siblings",[88],"2016-02","2008-02",[3346],"Autistic Disorder",[3331],{"trials":3349,"activeCount":99},[],{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[],{"intervention":3355,"totalTrials":132,"cells":3356},"Hydroxychloroquine",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3361,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[3363],{"nctId":3364,"briefTitle":3365,"status":2322,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":99,"conditions":3370,"interventions":3373},"NCT04363866","Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)",[88],"2021-03","2021-09","2020-08",[3371,3372],"COVID-19","SARS-CoV-2",[3355],{"trials":3375,"activeCount":99},[],{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[],{"intervention":3381,"totalTrials":132,"cells":3382},"Rituximab",{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3384,"activeCount":99},[],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[3389],{"nctId":3390,"briefTitle":3391,"status":123,"phases":3392,"primaryCompletion":1984,"completion":1984,"start":3393,"enrollment":22,"conditions":3394,"interventions":3397},"NCT00415506","Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation",[87,88],"2007-01",[3395,3396],"Scleritis","Orbital Disease",[3381],{"trials":3399,"activeCount":99},[],{"trials":3401,"activeCount":99},[],{"trials":3403,"activeCount":99},[],{"intervention":3405,"totalTrials":132,"cells":3406},"Botanical extract from Passiflora incarnata",{"EARLY_PHASE1":3407,"PHASE1":3409,"PHASE2":3411,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3408,"activeCount":99},[],{"trials":3410,"activeCount":99},[],{"trials":3412,"activeCount":99},[3413],{"nctId":3414,"briefTitle":3415,"status":2322,"phases":3416,"primaryCompletion":1891,"completion":1891,"start":168,"enrollment":99,"conditions":3417,"interventions":3419},"NCT00982787","Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy",[88],[3418],"Partial Epilepsy",[3405],{"trials":3421,"activeCount":99},[],{"trials":3423,"activeCount":99},[],{"trials":3425,"activeCount":99},[],{"intervention":3427,"totalTrials":132,"cells":3428},"Ipratropium Bromide",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3446,"PHASE4":3448,"NA":3450},{"trials":3430,"activeCount":99},[],{"trials":3432,"activeCount":99},[],{"trials":3434,"activeCount":99},[3435],{"nctId":3436,"briefTitle":3437,"status":123,"phases":3438,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":3442,"conditions":3443,"interventions":3445},"NCT06074185","Treating Respiratory Emergencies in Children Study",[88],"2025-02-28","2025-03-11","2024-01-19",44,[3444],"Asthma in Children",[3427],{"trials":3447,"activeCount":99},[],{"trials":3449,"activeCount":99},[],{"trials":3451,"activeCount":99},[],{"intervention":3453,"totalTrials":132,"cells":3454},"Albendazole",{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[],{"trials":3460,"activeCount":99},[3461],{"nctId":3462,"briefTitle":3463,"status":2322,"phases":3464,"primaryCompletion":3465,"completion":3465,"start":3466,"enrollment":99,"conditions":3467,"interventions":3469},"NCT03950037","SANCC: Clinical Trial Early Intervention",[88],"2023-04","2022-01-01",[3468],"Subarachnoid Neurocysticercosis",[3453],{"trials":3471,"activeCount":99},[],{"trials":3473,"activeCount":99},[],{"trials":3475,"activeCount":99},[],{"intervention":3477,"totalTrials":132,"cells":3478},"Lipoic acid and fish oil concentrate",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3492,"PHASE4":3494,"NA":3496},{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[],{"trials":3484,"activeCount":99},[3485],{"nctId":3486,"briefTitle":3487,"status":123,"phases":3488,"primaryCompletion":2982,"completion":2982,"start":3140,"enrollment":3489,"conditions":3490,"interventions":3491},"NCT01058941","Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease",[87,88],67,[840],[3477],{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"intervention":3499,"totalTrials":132,"cells":3500},"Omega 3 PUFA",{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3520,"PHASE4":3522,"NA":3524},{"trials":3502,"activeCount":99},[],{"trials":3504,"activeCount":99},[],{"trials":3506,"activeCount":99},[3507],{"nctId":3508,"briefTitle":3509,"status":1555,"phases":3510,"primaryCompletion":3511,"completion":3512,"start":3513,"enrollment":725,"conditions":3514,"interventions":3519},"NCT01953705","n-3 PUFA for Vascular Cognitive Aging",[88],"2020-12","2021-06","2014-05",[3515,840,3516,3517,3518],"Age Related Cognitive Decline","Vascular Dementia","Endothelial Dysfunction","Executive Dysfunction",[3499],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[],{"trials":3525,"activeCount":99},[],{"intervention":3527,"totalTrials":132,"cells":3528},"Lipoic Acid plus Omega-3 Fatty Acids",{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3533,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3530,"activeCount":99},[],{"trials":3532,"activeCount":99},[],{"trials":3534,"activeCount":99},[3535],{"nctId":3536,"briefTitle":3537,"status":123,"phases":3538,"primaryCompletion":3539,"completion":3539,"start":2100,"enrollment":1151,"conditions":3540,"interventions":3542},"NCT01780974","Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention",[87,88],"2015-10",[3541],"Treated Hypertension",[3527],{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[],{"intervention":3550,"totalTrials":132,"cells":3551},"emollient",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3553,"activeCount":99},[],{"trials":3555,"activeCount":99},[],{"trials":3557,"activeCount":99},[3558],{"nctId":3559,"briefTitle":3560,"status":123,"phases":3561,"primaryCompletion":3562,"completion":3081,"start":3563,"enrollment":19,"conditions":3564,"interventions":3565},"NCT00806221","An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis",[88],"2008-11","2006-11",[2488],[3550],{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[],{"trials":3571,"activeCount":99},[],{"intervention":3573,"totalTrials":132,"cells":3574},"Riboflavin",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3593,"PHASE4":3595,"NA":3597},{"trials":3576,"activeCount":99},[],{"trials":3578,"activeCount":99},[],{"trials":3580,"activeCount":99},[3581],{"nctId":3582,"briefTitle":3583,"status":1555,"phases":3584,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":467,"conditions":3588,"interventions":3592},"NCT04232800","Riboflavin for Glutamate Reduction in Alcohol Withdrawal",[88],"2022-08-25","2022-10-25","2021-12-01",[3589,3590,3591],"Alcohol Withdrawal","Nutrition Disorders","Alcohol Use Disorder",[3573],{"trials":3594,"activeCount":99},[],{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"intervention":3600,"totalTrials":132,"cells":3601},"Centella asiatica selected triterpenes",{"EARLY_PHASE1":3602,"PHASE1":3604,"PHASE2":3606,"PHASE3":3616,"PHASE4":3618,"NA":3620},{"trials":3603,"activeCount":99},[],{"trials":3605,"activeCount":99},[],{"trials":3607,"activeCount":99},[3608],{"nctId":3609,"briefTitle":3610,"status":123,"phases":3611,"primaryCompletion":167,"completion":167,"start":3612,"enrollment":11,"conditions":3613,"interventions":3615},"NCT00608439","Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy",[88],"2007-09",[3614],"Diabetic Neuropathy",[3600],{"trials":3617,"activeCount":99},[],{"trials":3619,"activeCount":99},[],{"trials":3621,"activeCount":99},[],{"intervention":3623,"totalTrials":132,"cells":3624},"Diuresis (furosemide) part I",{"EARLY_PHASE1":3625,"PHASE1":3627,"PHASE2":3629,"PHASE3":3642,"PHASE4":3644,"NA":3646},{"trials":3626,"activeCount":99},[],{"trials":3628,"activeCount":99},[],{"trials":3630,"activeCount":99},[3631],{"nctId":3632,"briefTitle":3633,"status":123,"phases":3634,"primaryCompletion":1891,"completion":1891,"start":3344,"enrollment":3635,"conditions":3636,"interventions":3638},"NCT00624650","Hemodynamics and Extravascular Lung Water in Acute Lung Injury",[88],33,[3637],"Acute Lung Injury",[3623,3639,3639,3640,3640,3641],"Vasopressors","Dobutamine","Diuresis (furosemide) part II",{"trials":3643,"activeCount":99},[],{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"intervention":3639,"totalTrials":132,"cells":3649},{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3660,"PHASE4":3662,"NA":3664},{"trials":3651,"activeCount":99},[],{"trials":3653,"activeCount":99},[],{"trials":3655,"activeCount":99},[3656],{"nctId":3632,"briefTitle":3633,"status":123,"phases":3657,"primaryCompletion":1891,"completion":1891,"start":3344,"enrollment":3635,"conditions":3658,"interventions":3659},[88],[3637],[3623,3639,3639,3640,3640,3641],{"trials":3661,"activeCount":99},[],{"trials":3663,"activeCount":99},[],{"trials":3665,"activeCount":99},[],{"intervention":3640,"totalTrials":132,"cells":3667},{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[3674],{"nctId":3632,"briefTitle":3633,"status":123,"phases":3675,"primaryCompletion":1891,"completion":1891,"start":3344,"enrollment":3635,"conditions":3676,"interventions":3677},[88],[3637],[3623,3639,3639,3640,3640,3641],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[],{"trials":3683,"activeCount":99},[],{"intervention":3641,"totalTrials":132,"cells":3685},{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3687,"activeCount":99},[],{"trials":3689,"activeCount":99},[],{"trials":3691,"activeCount":99},[3692],{"nctId":3632,"briefTitle":3633,"status":123,"phases":3693,"primaryCompletion":1891,"completion":1891,"start":3344,"enrollment":3635,"conditions":3694,"interventions":3695},[88],[3637],[3623,3639,3639,3640,3640,3641],{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[],{"trials":3701,"activeCount":99},[],{"intervention":3703,"totalTrials":132,"cells":3704},"Cinnamon",{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3720,"PHASE4":3722,"NA":3724},{"trials":3706,"activeCount":99},[],{"trials":3708,"activeCount":99},[],{"trials":3710,"activeCount":99},[3711],{"nctId":3712,"briefTitle":3713,"status":2322,"phases":3714,"primaryCompletion":3715,"completion":3715,"start":3716,"enrollment":99,"conditions":3717,"interventions":3719},"NCT02942056","The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus",[88],"2020-01","2017-01",[3718],"Diabetes Mellitus",[3703],{"trials":3721,"activeCount":99},[],{"trials":3723,"activeCount":99},[],{"trials":3725,"activeCount":99},[],{"intervention":3727,"totalTrials":132,"cells":3728},"Spironolactone 25mg",{"EARLY_PHASE1":3729,"PHASE1":3731,"PHASE2":3733,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3730,"activeCount":99},[],{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[3735],{"nctId":3736,"briefTitle":3737,"status":123,"phases":3738,"primaryCompletion":3739,"completion":3740,"start":3741,"enrollment":467,"conditions":3742,"interventions":3746},"NCT01069510","Spironolactone in Adult Congenital Heart Disease",[88],"2016-06","2017-03","2010-02",[3743,3744,3745],"Congenital Heart Disease","Heart Failure","Endomyocardial Fibrosis",[3727],{"trials":3748,"activeCount":99},[],{"trials":3750,"activeCount":99},[],{"trials":3752,"activeCount":99},[],{"intervention":3754,"totalTrials":132,"cells":3755},"Abatacept",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3757,"activeCount":99},[],{"trials":3759,"activeCount":99},[],{"trials":3761,"activeCount":99},[3762],{"nctId":3763,"briefTitle":3764,"status":123,"phases":3765,"primaryCompletion":3766,"completion":3766,"start":2046,"enrollment":1371,"conditions":3767,"interventions":3768},"NCT01279954","Abatacept in the Treatment of Uveitis",[88],"2017-06",[2761],[3754],{"trials":3770,"activeCount":99},[],{"trials":3772,"activeCount":99},[],{"trials":3774,"activeCount":99},[],{"intervention":3776,"totalTrials":132,"cells":3777},"Mitoquinone",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[],{"trials":3783,"activeCount":99},[3784],{"nctId":3785,"briefTitle":3786,"status":1322,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":3789,"enrollment":1892,"conditions":3790,"interventions":3791},"NCT03166800","MitoQ for Fatigue in Multiple Sclerosis",[87,88],"2019-01-10","2018-09-15",[21,3185],[3776,3776],{"trials":3793,"activeCount":99},[],{"trials":3795,"activeCount":99},[],{"trials":3797,"activeCount":99},[],{"intervention":3799,"totalTrials":132,"cells":3800},"Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3818,"PHASE4":3820,"NA":3822},{"trials":3802,"activeCount":99},[],{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[3807],{"nctId":3808,"briefTitle":3809,"status":123,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3817},"NCT03252522","Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study",[87,88],"2020-07-10","2021-05-31","2018-04-23",135,[3816],"Attention Deficit Hyperactivity Disorder",[3799],{"trials":3819,"activeCount":99},[],{"trials":3821,"activeCount":99},[],{"trials":3823,"activeCount":99},[],{"intervention":3825,"totalTrials":132,"cells":3826},"Triheptanoin",{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3828,"activeCount":99},[],{"trials":3830,"activeCount":99},[],{"trials":3832,"activeCount":99},[3833],{"nctId":3834,"briefTitle":3835,"status":123,"phases":3836,"primaryCompletion":3837,"completion":3837,"start":1847,"enrollment":1986,"conditions":3838,"interventions":3843},"NCT01379625","Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder",[88],"2015-04",[3839,3840,3841,3842],"Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency","Carnitine Palmitoyltransferase 2 (CPT2) Deficiency","Mitochondrial Trifunctional Protein (TFP) Deficiency","Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency",[3825],{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[],{"trials":3849,"activeCount":99},[],{"intervention":3851,"totalTrials":132,"cells":3852},"Ferumoxytol",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3869,"PHASE4":3871,"NA":3873},{"trials":3854,"activeCount":99},[],{"trials":3856,"activeCount":99},[],{"trials":3858,"activeCount":99},[3859],{"nctId":3860,"briefTitle":3861,"status":1322,"phases":3862,"primaryCompletion":3511,"completion":3863,"start":2849,"enrollment":3864,"conditions":3865,"interventions":3868},"NCT00659776","MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation",[88],"2021-12",255,[3866,3867],"Nervous System Diseases","Diagnostic Imaging",[3851],{"trials":3870,"activeCount":99},[],{"trials":3872,"activeCount":99},[],{"trials":3874,"activeCount":99},[],{"intervention":3876,"totalTrials":132,"cells":3877},"American ginseng extract HT-1001",{"EARLY_PHASE1":3878,"PHASE1":3880,"PHASE2":3882,"PHASE3":3891,"PHASE4":3893,"NA":3895},{"trials":3879,"activeCount":99},[],{"trials":3881,"activeCount":99},[],{"trials":3883,"activeCount":99},[3884],{"nctId":3885,"briefTitle":3886,"status":123,"phases":3887,"primaryCompletion":3888,"completion":1984,"start":1645,"enrollment":1141,"conditions":3889,"interventions":3890},"NCT00754832","American Ginseng Treatment for Multiple Sclerosis Related Fatigue",[88],"2008-09",[21],[3876],{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[],{"trials":3896,"activeCount":99},[],{"intervention":3898,"totalTrials":132,"cells":3899},"Fish oil concentrate",{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3901,"activeCount":99},[],{"trials":3903,"activeCount":99},[],{"trials":3905,"activeCount":99},[3906],{"nctId":3907,"briefTitle":3908,"status":123,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":3912,"conditions":3913,"interventions":3914},"NCT00122954","Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis",[87,88],"2009-06","2005-07",39,[21,33],[3898],{"trials":3916,"activeCount":99},[],{"trials":3918,"activeCount":99},[],{"trials":3920,"activeCount":99},[],{"intervention":3922,"totalTrials":132,"cells":3923},"Ixekizumab",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3939,"PHASE4":3941,"NA":3943},{"trials":3925,"activeCount":99},[],{"trials":3927,"activeCount":99},[],{"trials":3929,"activeCount":99},[3930],{"nctId":3931,"briefTitle":3932,"status":123,"phases":3933,"primaryCompletion":3934,"completion":3935,"start":3936,"enrollment":31,"conditions":3937,"interventions":3938},"NCT03485976","Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)",[88],"2019-10-14","2020-01-13","2018-05-23",[617],[3922],{"trials":3940,"activeCount":99},[],{"trials":3942,"activeCount":99},[],{"trials":3944,"activeCount":99},[],{"intervention":3946,"totalTrials":132,"cells":3947},"Baricitinib",{"EARLY_PHASE1":3948,"PHASE1":3950,"PHASE2":3952,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3949,"activeCount":99},[],{"trials":3951,"activeCount":99},[],{"trials":3953,"activeCount":99},[3954],{"nctId":3955,"briefTitle":3956,"status":123,"phases":3957,"primaryCompletion":3958,"completion":3959,"start":3960,"enrollment":1779,"conditions":3961,"interventions":3962},"NCT04901325","Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)",[88],"2025-01-05","2025-05-07","2023-10-03",[603,604,605,606,607],[3946],{"trials":3964,"activeCount":99},[],{"trials":3966,"activeCount":99},[],{"trials":3968,"activeCount":99},[],{"intervention":3970,"totalTrials":132,"cells":3971},"Contrast ultrasound of leg muscle with Sonazoid",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3987,"PHASE4":3989,"NA":3991},{"trials":3973,"activeCount":99},[],{"trials":3975,"activeCount":99},[],{"trials":3977,"activeCount":99},[3978],{"nctId":3979,"briefTitle":3980,"status":1555,"phases":3981,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":2239,"conditions":3984,"interventions":3986},"NCT02398266","Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid",[88],"2018-07-01","2016-08-01",[3985],"Peripheral Artery Disease",[3970],{"trials":3988,"activeCount":99},[],{"trials":3990,"activeCount":99},[],{"trials":3992,"activeCount":99},[],{"intervention":3994,"totalTrials":132,"cells":3995},"GSK2256294",{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4000,"PHASE3":4014,"PHASE4":4016,"NA":4018},{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[4002],{"nctId":4003,"briefTitle":4004,"status":123,"phases":4005,"primaryCompletion":4006,"completion":4007,"start":4008,"enrollment":22,"conditions":4009,"interventions":4013},"NCT03318783","Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial",[87,88],"2019-04-03","2020-01-09","2018-05-02",[4010,4011,4012,3517],"Subarachnoid Hemorrhage, Aneurysmal","Delayed Cerebral Ischemia","Vasospasm, Cerebral",[3994],{"trials":4015,"activeCount":99},[],{"trials":4017,"activeCount":99},[],{"trials":4019,"activeCount":99},[],{"intervention":4021,"totalTrials":132,"cells":4022},"XeriSol glucagon",{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4024,"activeCount":99},[],{"trials":4026,"activeCount":99},[4027],{"nctId":4028,"briefTitle":4029,"status":123,"phases":4030,"primaryCompletion":4031,"completion":4031,"start":4032,"enrollment":16,"conditions":4033,"interventions":4035},"NCT03424044","Three Way Crossover Closed Loop Study With Xeris Glucagon",[87],"2019-05-17","2018-03-29",[4034],"Type1diabetes",[4021],{"trials":4037,"activeCount":99},[],{"trials":4039,"activeCount":99},[],{"trials":4041,"activeCount":99},[],{"trials":4043,"activeCount":99},[],{"intervention":4045,"totalTrials":132,"cells":4046},"Salvia officinalis",{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4061,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4048,"activeCount":99},[],{"trials":4050,"activeCount":99},[4051],{"nctId":4052,"briefTitle":4053,"status":123,"phases":4054,"primaryCompletion":4055,"completion":4056,"start":3911,"enrollment":4057,"conditions":4058,"interventions":4060},"NCT00110552","Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients",[87],"2012-12","2014-10",111,[4059],"Alzheimer Disease",[4045],{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[],{"trials":4066,"activeCount":99},[],{"trials":4068,"activeCount":99},[],{"intervention":4070,"totalTrials":132,"cells":4071},"ursodiol",{"EARLY_PHASE1":4072,"PHASE1":4074,"PHASE2":4084,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4073,"activeCount":99},[],{"trials":4075,"activeCount":99},[4076],{"nctId":4077,"briefTitle":4078,"status":1555,"phases":4079,"primaryCompletion":3910,"completion":3910,"start":1531,"enrollment":4080,"conditions":4081,"interventions":4083},"NCT00514774","Ursodiol in Huntington's Disease",[87],21,[4082],"Huntington Disease",[4070],{"trials":4085,"activeCount":99},[],{"trials":4087,"activeCount":99},[],{"trials":4089,"activeCount":99},[],{"trials":4091,"activeCount":99},[],{"intervention":4093,"totalTrials":132,"cells":4094},"Buspirone",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4110,"PHASE3":4112,"PHASE4":4114,"NA":4116},{"trials":4096,"activeCount":99},[],{"trials":4098,"activeCount":99},[4099],{"nctId":4100,"briefTitle":4101,"status":1322,"phases":4102,"primaryCompletion":4103,"completion":4103,"start":4104,"enrollment":4105,"conditions":4106,"interventions":4109},"NCT02589340","Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia",[87],"2021-02-23","2016-01",6,[15,4107,4108],"Dyskinesias","Movement Disorders",[4093],{"trials":4111,"activeCount":99},[],{"trials":4113,"activeCount":99},[],{"trials":4115,"activeCount":99},[],{"trials":4117,"activeCount":99},[],{"intervention":4119,"totalTrials":132,"cells":4120},"oral lipoic acid",{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4133,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4122,"activeCount":99},[],{"trials":4124,"activeCount":99},[4125],{"nctId":4126,"briefTitle":4127,"status":123,"phases":4128,"primaryCompletion":3344,"completion":3562,"start":1530,"enrollment":467,"conditions":4129,"interventions":4130},"NCT00676156","A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis",[87],[21],[4119,4131,4132],"lipoic acid (LA) with fish oil and LA without fish oil","R lipoic acid",{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[],{"trials":4138,"activeCount":99},[],{"trials":4140,"activeCount":99},[],{"intervention":4131,"totalTrials":132,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4151,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4144,"activeCount":99},[],{"trials":4146,"activeCount":99},[4147],{"nctId":4126,"briefTitle":4127,"status":123,"phases":4148,"primaryCompletion":3344,"completion":3562,"start":1530,"enrollment":467,"conditions":4149,"interventions":4150},[87],[21],[4119,4131,4132],{"trials":4152,"activeCount":99},[],{"trials":4154,"activeCount":99},[],{"trials":4156,"activeCount":99},[],{"trials":4158,"activeCount":99},[],{"intervention":4132,"totalTrials":132,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4169,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4162,"activeCount":99},[],{"trials":4164,"activeCount":99},[4165],{"nctId":4126,"briefTitle":4127,"status":123,"phases":4166,"primaryCompletion":3344,"completion":3562,"start":1530,"enrollment":467,"conditions":4167,"interventions":4168},[87],[21],[4119,4131,4132],{"trials":4170,"activeCount":99},[],{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[],{"trials":4176,"activeCount":99},[],{"intervention":4178,"totalTrials":132,"cells":4179},"Liothyronine sodium",{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4192,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4181,"activeCount":99},[],{"trials":4183,"activeCount":99},[4184],{"nctId":4185,"briefTitle":4186,"status":123,"phases":4187,"primaryCompletion":4188,"completion":4188,"start":4189,"enrollment":28,"conditions":4190,"interventions":4191},"NCT02760056","Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study",[87],"2017-01-10","2016-06-06",[21],[4178],{"trials":4193,"activeCount":99},[],{"trials":4195,"activeCount":99},[],{"trials":4197,"activeCount":99},[],{"trials":4199,"activeCount":99},[],{"intervention":4201,"totalTrials":132,"cells":4202},"Acamprosate",{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4215,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4204,"activeCount":99},[],{"trials":4206,"activeCount":99},[4207],{"nctId":4208,"briefTitle":4209,"status":123,"phases":4210,"primaryCompletion":2238,"completion":2238,"start":3297,"enrollment":4211,"conditions":4212,"interventions":4214},"NCT00596531","Clinical Trial of Acamprosate for Tinnitus",[87],154,[4213],"Tinnitus",[4201],{"trials":4216,"activeCount":99},[],{"trials":4218,"activeCount":99},[],{"trials":4220,"activeCount":99},[],{"trials":4222,"activeCount":99},[],{"intervention":4224,"totalTrials":132,"cells":4225},"Raptiva",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4238,"PHASE3":4240,"PHASE4":4242,"NA":4244},{"trials":4227,"activeCount":99},[],{"trials":4229,"activeCount":99},[4230],{"nctId":4231,"briefTitle":4232,"status":123,"phases":4233,"primaryCompletion":4234,"completion":2642,"start":2280,"enrollment":1371,"conditions":4235,"interventions":4237},"NCT00226057","Efalizumab for Moderate to Severe Atopic Dermatitis",[87],"2005-11",[4236],"Dermatitis, Atopic",[4224],{"trials":4239,"activeCount":99},[],{"trials":4241,"activeCount":99},[],{"trials":4243,"activeCount":99},[],{"trials":4245,"activeCount":99},[],{"intervention":4247,"totalTrials":132,"cells":4248},"N-acetylcysteine",{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4262,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4250,"activeCount":99},[],{"trials":4252,"activeCount":99},[4253],{"nctId":4254,"briefTitle":4255,"status":1322,"phases":4256,"primaryCompletion":4257,"completion":4257,"start":4258,"enrollment":4105,"conditions":4259,"interventions":4261},"NCT00575419","Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w\u002FStage 3 Renal Failure",[87],"2014-09-15","2007-11",[4260],"Contrast Induced Nephropathy",[4247],{"trials":4263,"activeCount":99},[],{"trials":4265,"activeCount":99},[],{"trials":4267,"activeCount":99},[],{"trials":4269,"activeCount":99},[],{"intervention":4271,"totalTrials":132,"cells":4272},"pramipexole",{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4284,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4274,"activeCount":99},[],{"trials":4276,"activeCount":99},[4277],{"nctId":4278,"briefTitle":4279,"status":123,"phases":4280,"primaryCompletion":2368,"completion":2368,"start":4281,"enrollment":2850,"conditions":4282,"interventions":4283},"NCT00666653","Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease",[87],"2003-07",[15],[4271],{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[],{"intervention":4293,"totalTrials":132,"cells":4294},"FEIBA",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[4299],{"nctId":4300,"briefTitle":4301,"status":123,"phases":4302,"primaryCompletion":4303,"completion":4304,"start":3343,"enrollment":31,"conditions":4305,"interventions":4307},"NCT02577614","FEIBA and Use of Blood Products in Cardiac Surgery",[87],"2019-12","2020-03",[4306],"Cardiovascular Disease",[4293,4308],"Normal Saline",{"trials":4310,"activeCount":99},[],{"trials":4312,"activeCount":99},[],{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"intervention":4308,"totalTrials":132,"cells":4318},{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4327,"PHASE3":4329,"PHASE4":4331,"NA":4333},{"trials":4320,"activeCount":99},[],{"trials":4322,"activeCount":99},[4323],{"nctId":4300,"briefTitle":4301,"status":123,"phases":4324,"primaryCompletion":4303,"completion":4304,"start":3343,"enrollment":31,"conditions":4325,"interventions":4326},[87],[4306],[4293,4308],{"trials":4328,"activeCount":99},[],{"trials":4330,"activeCount":99},[],{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"intervention":4336,"totalTrials":132,"cells":4337},"Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial",{"EARLY_PHASE1":4338,"PHASE1":4340,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4363},{"trials":4339,"activeCount":99},[],{"trials":4341,"activeCount":99},[4342],{"nctId":4343,"briefTitle":4344,"status":123,"phases":4345,"primaryCompletion":4346,"completion":4347,"start":4348,"enrollment":1779,"conditions":4349,"interventions":4353},"NCT03793439","Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis",[87],"2020-06-24","2021-06-24","2019-05-15",[4350,4351,4352],"Sarcoidosis, Pulmonary","Sarcoidosis Lung","Sarcoidosis",[4336,4354,4355,4356],"RNA Sequencing","Corticosteroid","Tofacitinib 5mg [Xeljanz] 1 year open-label extension",{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[],{"trials":4362,"activeCount":99},[],{"trials":4364,"activeCount":99},[],{"intervention":4354,"totalTrials":132,"cells":4366},{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4375,"PHASE3":4377,"PHASE4":4379,"NA":4381},{"trials":4368,"activeCount":99},[],{"trials":4370,"activeCount":99},[4371],{"nctId":4343,"briefTitle":4344,"status":123,"phases":4372,"primaryCompletion":4346,"completion":4347,"start":4348,"enrollment":1779,"conditions":4373,"interventions":4374},[87],[4350,4351,4352],[4336,4354,4355,4356],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"trials":4380,"activeCount":99},[],{"trials":4382,"activeCount":99},[],{"intervention":4355,"totalTrials":132,"cells":4384},{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4393,"PHASE3":4395,"PHASE4":4397,"NA":4399},{"trials":4386,"activeCount":99},[],{"trials":4388,"activeCount":99},[4389],{"nctId":4343,"briefTitle":4344,"status":123,"phases":4390,"primaryCompletion":4346,"completion":4347,"start":4348,"enrollment":1779,"conditions":4391,"interventions":4392},[87],[4350,4351,4352],[4336,4354,4355,4356],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[],{"trials":4398,"activeCount":99},[],{"trials":4400,"activeCount":99},[],{"intervention":4356,"totalTrials":132,"cells":4402},{"EARLY_PHASE1":4403,"PHASE1":4405,"PHASE2":4411,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4404,"activeCount":99},[],{"trials":4406,"activeCount":99},[4407],{"nctId":4343,"briefTitle":4344,"status":123,"phases":4408,"primaryCompletion":4346,"completion":4347,"start":4348,"enrollment":1779,"conditions":4409,"interventions":4410},[87],[4350,4351,4352],[4336,4354,4355,4356],{"trials":4412,"activeCount":99},[],{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[],{"intervention":4420,"totalTrials":95,"cells":4421},"2g Centella asiatica water extract product",{"EARLY_PHASE1":4422,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4423,"activeCount":99},[4424,4435],{"nctId":4425,"briefTitle":4426,"status":1322,"phases":4427,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":1779,"conditions":4430,"interventions":4433},"NCT03937908","Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment",[86],"2020-12-21","2019-10-31",[4431,4432],"Cognitive Impairment","Elderly",[4420,4434],"4g Centella asiatica water extract product",{"nctId":4436,"briefTitle":4437,"status":123,"phases":4438,"primaryCompletion":4439,"completion":4440,"start":4441,"enrollment":1936,"conditions":4442,"interventions":4444},"NCT03929250","Pharmacokinetics of Centella Asiatica in the Elderly",[86],"2019-11-30","2024-01-03","2019-07-05",[4443,4432],"Healthy",[4420,4434],{"trials":4446,"activeCount":99},[],{"trials":4448,"activeCount":99},[],{"trials":4450,"activeCount":99},[],{"trials":4452,"activeCount":99},[],{"trials":4454,"activeCount":99},[],{"intervention":4434,"totalTrials":95,"cells":4456},{"EARLY_PHASE1":4457,"PHASE1":4467,"PHASE2":4469,"PHASE3":4471,"PHASE4":4473,"NA":4475},{"trials":4458,"activeCount":99},[4459,4463],{"nctId":4425,"briefTitle":4426,"status":1322,"phases":4460,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":1779,"conditions":4461,"interventions":4462},[86],[4431,4432],[4420,4434],{"nctId":4436,"briefTitle":4437,"status":123,"phases":4464,"primaryCompletion":4439,"completion":4440,"start":4441,"enrollment":1936,"conditions":4465,"interventions":4466},[86],[4443,4432],[4420,4434],{"trials":4468,"activeCount":99},[],{"trials":4470,"activeCount":99},[],{"trials":4472,"activeCount":99},[],{"trials":4474,"activeCount":99},[],{"trials":4476,"activeCount":99},[],{"intervention":4478,"totalTrials":132,"cells":4479},"Sonazoid",{"EARLY_PHASE1":4480,"PHASE1":4490,"PHASE2":4492,"PHASE3":4494,"PHASE4":4496,"NA":4498},{"trials":4481,"activeCount":99},[4482],{"nctId":4483,"briefTitle":4484,"status":1555,"phases":4485,"primaryCompletion":4303,"completion":4303,"start":4486,"enrollment":467,"conditions":4487,"interventions":4489},"NCT03009266","Ischemic Memory Imaging With Myocardial Contrast Echocardiography",[86],"2018-07-07",[4488],"Myocardial Ischemia",[4478],{"trials":4491,"activeCount":99},[],{"trials":4493,"activeCount":99},[],{"trials":4495,"activeCount":99},[],{"trials":4497,"activeCount":99},[],{"trials":4499,"activeCount":99},[],{"intervention":4501,"totalTrials":132,"cells":4502},"Testosterone",{"EARLY_PHASE1":4503,"PHASE1":4516,"PHASE2":4518,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4504,"activeCount":99},[4505],{"nctId":4506,"briefTitle":4507,"status":123,"phases":4508,"primaryCompletion":1601,"completion":4509,"start":4510,"enrollment":4511,"conditions":4512,"interventions":4515},"NCT03864913","Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents",[86],"2019-12-30","2018-01-26",26,[4513,4514],"Health Services for Transgender Persons","Transgender Persons",[4501],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[],{"intervention":4527,"totalTrials":132,"cells":4528},"Terbinafine",{"EARLY_PHASE1":4529,"PHASE1":4545,"PHASE2":4547,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4530,"activeCount":99},[4531],{"nctId":4532,"briefTitle":4533,"status":2322,"phases":4534,"primaryCompletion":4535,"completion":4536,"start":4537,"enrollment":99,"conditions":4538,"interventions":4544},"NCT05119712","Terbinafine Treatment of Axial Spondyloarthropathy",[86],"2023-10-15","2024-10-15","2021-03-09",[4539,4540,4541,4542,4543],"Ankylosing Spondylitis","Axial Spondyloarthritis","Psoriatic Spondylitis","Spondylitis Secondary to Inflammatory Bowel Disease","Axial Spondyloarthopathy",[4527],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[],{"trials":4550,"activeCount":99},[],{"trials":4552,"activeCount":99},[],{"trials":4554,"activeCount":99},[],{"intervention":4556,"totalTrials":132,"cells":4557},"Dronabinol",{"EARLY_PHASE1":4558,"PHASE1":4572,"PHASE2":4574,"PHASE3":4576,"PHASE4":4578,"NA":4580},{"trials":4559,"activeCount":99},[4560],{"nctId":4561,"briefTitle":4562,"status":123,"phases":4563,"primaryCompletion":4564,"completion":75,"start":4565,"enrollment":25,"conditions":4566,"interventions":4571},"NCT03560934","Tetrahydrocannabinol (THC) and Sleep",[86],"2021-09-19","2018-09-01",[4567,4568,4569,4570],"Sleep","THC","Marijuana","Cannabis",[4556],{"trials":4573,"activeCount":99},[],{"trials":4575,"activeCount":99},[],{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[],{"trials":4581,"activeCount":99},[],{"intervention":4583,"totalTrials":132,"cells":4584},"Preservative free 1% Chloroprocaine",{"EARLY_PHASE1":4585,"PHASE1":4598,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4586,"activeCount":99},[4587],{"nctId":4588,"briefTitle":4589,"status":123,"phases":4590,"primaryCompletion":4591,"completion":4592,"start":4593,"enrollment":28,"conditions":4594,"interventions":4595},"NCT03760718","Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery",[86],"2020-09-17","2021-12-31","2019-09-30",[1007],[4583,4596,4597],"Preservative free 2% Chloroprocaine","Preservative free 3% Chloroprocaine",{"trials":4599,"activeCount":99},[],{"trials":4601,"activeCount":99},[],{"trials":4603,"activeCount":99},[],{"trials":4605,"activeCount":99},[],{"trials":4607,"activeCount":99},[],{"intervention":4596,"totalTrials":132,"cells":4609},{"EARLY_PHASE1":4610,"PHASE1":4616,"PHASE2":4618,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4611,"activeCount":99},[4612],{"nctId":4588,"briefTitle":4589,"status":123,"phases":4613,"primaryCompletion":4591,"completion":4592,"start":4593,"enrollment":28,"conditions":4614,"interventions":4615},[86],[1007],[4583,4596,4597],{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"trials":4621,"activeCount":99},[],{"trials":4623,"activeCount":99},[],{"trials":4625,"activeCount":99},[],{"intervention":4597,"totalTrials":132,"cells":4627},{"EARLY_PHASE1":4628,"PHASE1":4634,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4629,"activeCount":99},[4630],{"nctId":4588,"briefTitle":4589,"status":123,"phases":4631,"primaryCompletion":4591,"completion":4592,"start":4593,"enrollment":28,"conditions":4632,"interventions":4633},[86],[1007],[4583,4596,4597],{"trials":4635,"activeCount":99},[],{"trials":4637,"activeCount":99},[],{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"trials":4643,"activeCount":99},[],{"intervention":4645,"totalTrials":132,"cells":4646},"Entacapone",{"EARLY_PHASE1":4647,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4666},{"trials":4648,"activeCount":99},[4649],{"nctId":4650,"briefTitle":4651,"status":123,"phases":4652,"primaryCompletion":3739,"completion":3739,"start":3207,"enrollment":4653,"conditions":4654,"interventions":4656},"NCT02058966","Pilot Study of Entacapone for Methamphetamine Abuse",[86],29,[4655],"Methamphetamine Dependence",[4645,4657],"Methamphetamine",{"trials":4659,"activeCount":99},[],{"trials":4661,"activeCount":99},[],{"trials":4663,"activeCount":99},[],{"trials":4665,"activeCount":99},[],{"trials":4667,"activeCount":99},[],{"intervention":4657,"totalTrials":132,"cells":4669},{"EARLY_PHASE1":4670,"PHASE1":4676,"PHASE2":4678,"PHASE3":4680,"PHASE4":4682,"NA":4684},{"trials":4671,"activeCount":99},[4672],{"nctId":4650,"briefTitle":4651,"status":123,"phases":4673,"primaryCompletion":3739,"completion":3739,"start":3207,"enrollment":4653,"conditions":4674,"interventions":4675},[86],[4655],[4645,4657],{"trials":4677,"activeCount":99},[],{"trials":4679,"activeCount":99},[],{"trials":4681,"activeCount":99},[],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[],{"intervention":4687,"totalTrials":132,"cells":4688},"Fludrocortisone",{"EARLY_PHASE1":4689,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4708},{"trials":4690,"activeCount":99},[4691],{"nctId":4692,"briefTitle":4693,"status":1322,"phases":4694,"primaryCompletion":4695,"completion":4695,"start":4696,"enrollment":1779,"conditions":4697,"interventions":4699},"NCT01186185","Fludrocortisone for Sudden Hearing Loss",[86],"2016-03","2012-08",[4698],"Hearing Loss, Sensorineural",[4687],{"trials":4701,"activeCount":99},[],{"trials":4703,"activeCount":99},[],{"trials":4705,"activeCount":99},[],{"trials":4707,"activeCount":99},[],{"trials":4709,"activeCount":99},[],{"intervention":4711,"totalTrials":132,"cells":4712},"topical 0.5% Timolol",{"EARLY_PHASE1":4713,"PHASE1":4727,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4714,"activeCount":99},[4715],{"nctId":4716,"briefTitle":4717,"status":1322,"phases":4718,"primaryCompletion":4719,"completion":4720,"start":4721,"enrollment":4105,"conditions":4722,"interventions":4725},"NCT01147601","Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas",[86],"2012-10","2014-08","2010-03",[4723,4724],"Hemangioma","Infant",[4711,4726],"Control (placebo) group",{"trials":4728,"activeCount":99},[],{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[],{"trials":4736,"activeCount":99},[],{"intervention":4726,"totalTrials":132,"cells":4738},{"EARLY_PHASE1":4739,"PHASE1":4745,"PHASE2":4747,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4740,"activeCount":99},[4741],{"nctId":4716,"briefTitle":4717,"status":1322,"phases":4742,"primaryCompletion":4719,"completion":4720,"start":4721,"enrollment":4105,"conditions":4743,"interventions":4744},[86],[4723,4724],[4711,4726],{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[],{"trials":4754,"activeCount":99},[],{"intervention":4756,"totalTrials":132,"cells":4757},"Growth hormone",{"EARLY_PHASE1":4758,"PHASE1":4766,"PHASE2":4768,"PHASE3":4770,"PHASE4":4772,"NA":4774},{"trials":4759,"activeCount":99},[4760],{"nctId":4761,"briefTitle":4762,"status":123,"phases":4763,"primaryCompletion":2046,"completion":2046,"start":2643,"enrollment":796,"conditions":4764,"interventions":4765},"NCT00517062","Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates",[86],[2148],[4756],{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[],{"intervention":4777,"totalTrials":4105,"cells":4778},"Melatonin",{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4783,"PHASE3":4794,"PHASE4":4796,"NA":4798},{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"trials":4784,"activeCount":99},[4785],{"nctId":4786,"briefTitle":4787,"status":123,"phases":4788,"primaryCompletion":416,"completion":416,"start":4789,"enrollment":4080,"conditions":4790,"interventions":4792},"NCT04932096","Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin",[88],"2023-01-02",[2941,4791,4567],"Critical Illness",[4793],"melatonin",{"trials":4795,"activeCount":99},[],{"trials":4797,"activeCount":99},[],{"trials":4799,"activeCount":99},[4800,4808,4819,4825,4832],{"nctId":4801,"briefTitle":4802,"status":1322,"phases":4803,"primaryCompletion":4804,"completion":4804,"start":2047,"enrollment":1892,"conditions":4805,"interventions":4807},"NCT00688935","Young Blind Child Melatonin Treatment Study",[91],"2015-05",[4806],"Blindness",[4777],{"nctId":4809,"briefTitle":4810,"status":1322,"phases":4811,"primaryCompletion":4812,"completion":4812,"start":4813,"enrollment":4814,"conditions":4815,"interventions":4818},"NCT00911053","Melatonin for Circadian Sleep Disorders in the Blind",[91],"2012-06","1997-06",59,[4816,4806,4817],"Insomnia","Daytime Sleepiness",[4777],{"nctId":4820,"briefTitle":4821,"status":1322,"phases":4822,"primaryCompletion":1139,"completion":1139,"start":3254,"enrollment":1371,"conditions":4823,"interventions":4824},"NCT00691444","Blind Child Melatonin Treatment Study",[91],[4806],[4777],{"nctId":4826,"briefTitle":4827,"status":1322,"phases":4828,"primaryCompletion":2145,"completion":3141,"start":4829,"enrollment":31,"conditions":4830,"interventions":4831},"NCT00692094","Blind Elderly Melatonin Treatment Study",[91],"2004-08",[4806],[4777,4777,4777,4777],{"nctId":4833,"briefTitle":4834,"status":1322,"phases":4835,"primaryCompletion":4836,"completion":4836,"start":3081,"enrollment":2850,"conditions":4837,"interventions":4839},"NCT00795236","Melatonin Studies of Totally Blind Children",[91],"2015-06",[4838,4806],"Sleep Disorder",[4777],{"intervention":4841,"totalTrials":1326,"cells":4842},"Donepezil",{"EARLY_PHASE1":4843,"PHASE1":4854,"PHASE2":4856,"PHASE3":4866,"PHASE4":4868,"NA":4878},{"trials":4844,"activeCount":99},[4845],{"nctId":4846,"briefTitle":4847,"status":123,"phases":4848,"primaryCompletion":4849,"completion":4850,"start":4851,"enrollment":22,"conditions":4852,"interventions":4853},"NCT03599726","Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil",[86],"2019-05-30","2019-07-30","2018-07-30",[36],[4841],{"trials":4855,"activeCount":99},[],{"trials":4857,"activeCount":99},[4858],{"nctId":4859,"briefTitle":4860,"status":123,"phases":4861,"primaryCompletion":4862,"completion":4862,"start":2391,"enrollment":4863,"conditions":4864,"interventions":4865},"NCT02206620","Effects of Cholinergic Augmentation on Measures of Balance and Gait",[88],"2017-07",49,[15],[4841],{"trials":4867,"activeCount":99},[],{"trials":4869,"activeCount":99},[4870],{"nctId":4871,"briefTitle":4872,"status":123,"phases":4873,"primaryCompletion":4874,"completion":4875,"start":1985,"enrollment":4080,"conditions":4876,"interventions":4877},"NCT01521117","The Effect of Donepezil on Gait and Balance in Parkinson's Disease",[90],"2012-04","2012-07",[15],[4841],{"trials":4879,"activeCount":99},[4880],{"nctId":4881,"briefTitle":4882,"status":123,"phases":4883,"primaryCompletion":3056,"completion":3056,"start":3117,"enrollment":16,"conditions":4884,"interventions":4885},"NCT00912808","Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease",[91],[15],[4841,4886],"Sugar Pill",{"intervention":2107,"totalTrials":1123,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4895,"PHASE4":4897,"NA":4907},{"trials":4890,"activeCount":99},[],{"trials":4892,"activeCount":99},[],{"trials":4894,"activeCount":99},[],{"trials":4896,"activeCount":99},[],{"trials":4898,"activeCount":99},[4899,4903],{"nctId":2095,"briefTitle":2096,"status":123,"phases":4900,"primaryCompletion":2098,"completion":2099,"start":2100,"enrollment":2101,"conditions":4901,"interventions":4902},[90],[27,2103,2104],[2082,2106,2107],{"nctId":2364,"briefTitle":2365,"status":123,"phases":4904,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1688,"conditions":4905,"interventions":4906},[90],[27],[2107,2351],{"trials":4908,"activeCount":99},[4909],{"nctId":4910,"briefTitle":4911,"status":123,"phases":4912,"primaryCompletion":2145,"completion":2145,"start":3612,"enrollment":927,"conditions":4913,"interventions":4914},"NCT00613821","Lidocaine and Pain Management in First Trimester Abortions",[91],[27],[2107,2107],{"intervention":4916,"totalTrials":95,"cells":4917},"Celebrex",{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4928},{"trials":4919,"activeCount":99},[],{"trials":4921,"activeCount":99},[],{"trials":4923,"activeCount":99},[],{"trials":4925,"activeCount":99},[],{"trials":4927,"activeCount":99},[],{"trials":4929,"activeCount":99},[4930,4939],{"nctId":4931,"briefTitle":4932,"status":123,"phases":4933,"primaryCompletion":2828,"completion":2828,"start":3297,"enrollment":34,"conditions":4934,"interventions":4938},"NCT00614406","The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle",[91],[4935,4936,4937],"Ovulation (Follicular Rupture Yes\u002Fno)","Menstrual Cycles (Total Length, Bleeding Days)","Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)",[4916],{"nctId":4940,"briefTitle":4941,"status":123,"phases":4942,"primaryCompletion":1847,"completion":1847,"start":168,"enrollment":22,"conditions":4943,"interventions":4946},"NCT01129245","The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation",[91],[4944,4945],"Ovulation","Luteal Development",[4916],{"intervention":1783,"totalTrials":95,"cells":4948},{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4955,"PHASE4":4957,"NA":4963},{"trials":4950,"activeCount":99},[],{"trials":4952,"activeCount":99},[],{"trials":4954,"activeCount":99},[],{"trials":4956,"activeCount":99},[],{"trials":4958,"activeCount":99},[4959],{"nctId":1774,"briefTitle":1775,"status":123,"phases":4960,"primaryCompletion":1777,"completion":1777,"start":1778,"enrollment":1779,"conditions":4961,"interventions":4962},[90],[1781,24],[1783,1761,1784],{"trials":4964,"activeCount":99},[4965],{"nctId":4966,"briefTitle":4967,"status":123,"phases":4968,"primaryCompletion":4812,"completion":1890,"start":4969,"enrollment":1779,"conditions":4970,"interventions":4972},"NCT01546454","Relationship Between the Menstrual Cycle and Heart Disease in Women",[91],"2012-02",[4971],"Coronary Heart Disease",[4973,4974,4975,4976],"Ethinyl Estradiol-Levonorgestrel combination","leuprolide acetate","Estradiol","Progesterone",{"intervention":4978,"totalTrials":95,"cells":4979},"Retrobulbar Block or General Anesthesia",{"EARLY_PHASE1":4980,"PHASE1":4982,"PHASE2":4984,"PHASE3":4986,"PHASE4":4988,"NA":4990},{"trials":4981,"activeCount":99},[],{"trials":4983,"activeCount":99},[],{"trials":4985,"activeCount":99},[],{"trials":4987,"activeCount":99},[],{"trials":4989,"activeCount":99},[],{"trials":4991,"activeCount":99},[4992,5001],{"nctId":4993,"briefTitle":4994,"status":1322,"phases":4995,"primaryCompletion":4996,"completion":4996,"start":2827,"enrollment":1779,"conditions":4997,"interventions":4999},"NCT01901614","OCT-guided LALAK for KCN",[91],"2017-08-31",[984,4998],"Keratoconus",[4978,5000],"Topical Anesthesia",{"nctId":5002,"briefTitle":5003,"status":2322,"phases":5004,"primaryCompletion":4996,"completion":4996,"start":2860,"enrollment":99,"conditions":5005,"interventions":5007},"NCT01901601","LALAK for Opacities",[91],[5006],"STROMAL OPACITIES",[4978,5000],{"intervention":5000,"totalTrials":95,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5011,"activeCount":99},[],{"trials":5013,"activeCount":99},[],{"trials":5015,"activeCount":99},[],{"trials":5017,"activeCount":99},[],{"trials":5019,"activeCount":99},[],{"trials":5021,"activeCount":99},[5022,5026],{"nctId":4993,"briefTitle":4994,"status":1322,"phases":5023,"primaryCompletion":4996,"completion":4996,"start":2827,"enrollment":1779,"conditions":5024,"interventions":5025},[91],[984,4998],[4978,5000],{"nctId":5002,"briefTitle":5003,"status":2322,"phases":5027,"primaryCompletion":4996,"completion":4996,"start":2860,"enrollment":99,"conditions":5028,"interventions":5029},[91],[5006],[4978,5000],{"intervention":5031,"totalTrials":95,"cells":5032},"pioglitazone",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5039,"PHASE4":5041,"NA":5043},{"trials":5034,"activeCount":99},[],{"trials":5036,"activeCount":99},[],{"trials":5038,"activeCount":99},[],{"trials":5040,"activeCount":99},[],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[5045,5052],{"nctId":5046,"briefTitle":5047,"status":1322,"phases":5048,"primaryCompletion":3232,"completion":3232,"start":3056,"enrollment":4105,"conditions":5049,"interventions":5051},"NCT00843791","Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin",[91],[18,5050],"Insulin Resistance",[5031],{"nctId":5053,"briefTitle":5054,"status":123,"phases":5055,"primaryCompletion":982,"completion":3088,"start":1644,"enrollment":5056,"conditions":5057,"interventions":5059},"NCT00694759","Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)",[91],37,[5058],"Polycystic Ovary Syndrome",[5031,5060],"metformin",{"intervention":2051,"totalTrials":95,"cells":5062},{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5071,"NA":5077},{"trials":5064,"activeCount":99},[],{"trials":5066,"activeCount":99},[],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"trials":5072,"activeCount":99},[5073],{"nctId":2043,"briefTitle":2044,"status":1555,"phases":5074,"primaryCompletion":2046,"start":2047,"enrollment":927,"conditions":5075,"interventions":5076},[90],[2049],[2051,2030],{"trials":5078,"activeCount":99},[5079],{"nctId":5080,"briefTitle":5081,"status":1322,"phases":5082,"primaryCompletion":4056,"completion":4056,"start":1847,"enrollment":132,"conditions":5083,"interventions":5085},"NCT01434745","SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation",[91],[5084],"Smith-Lemli-Opitz Syndrome",[2051],{"intervention":5087,"totalTrials":95,"cells":5088},"Extended Release Naltrexone",{"EARLY_PHASE1":5089,"PHASE1":5091,"PHASE2":5093,"PHASE3":5095,"PHASE4":5106,"NA":5108},{"trials":5090,"activeCount":99},[],{"trials":5092,"activeCount":99},[],{"trials":5094,"activeCount":99},[],{"trials":5096,"activeCount":99},[5097],{"nctId":5098,"briefTitle":5099,"status":123,"phases":5100,"primaryCompletion":5101,"completion":5101,"start":3207,"enrollment":5102,"conditions":5103,"interventions":5105},"NCT01908062","Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study",[89],"2015-03",51,[5104,3591],"Opioid Use Disorder",[5087],{"trials":5107,"activeCount":99},[],{"trials":5109,"activeCount":99},[5110],{"nctId":5111,"briefTitle":5112,"status":123,"phases":5113,"primaryCompletion":5101,"completion":5101,"start":1753,"enrollment":5114,"conditions":5115,"interventions":5117},"NCT01822132","Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade",[91],76,[5116,2442],"Methamphetamine Abuse",[5118],"Extended release naltrexone",{"intervention":5120,"totalTrials":95,"cells":5121},"Metformin",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5141},{"trials":5123,"activeCount":99},[],{"trials":5125,"activeCount":99},[],{"trials":5127,"activeCount":99},[],{"trials":5129,"activeCount":99},[],{"trials":5131,"activeCount":99},[5132],{"nctId":5133,"briefTitle":5134,"status":123,"phases":5135,"primaryCompletion":5136,"completion":5136,"start":5137,"enrollment":467,"conditions":5138,"interventions":5140},"NCT06280274","Metformin Use in Patients Undergoing Total Joint Replacement Surgery",[90],"2025-09-15","2024-06-27",[5139],"Hyperglycemia",[5120],{"trials":5142,"activeCount":99},[5143],{"nctId":5053,"briefTitle":5054,"status":123,"phases":5144,"primaryCompletion":982,"completion":3088,"start":1644,"enrollment":5056,"conditions":5145,"interventions":5146},[91],[5058],[5031,5060],{"intervention":4886,"totalTrials":95,"cells":5148},{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5150,"activeCount":99},[],{"trials":5152,"activeCount":99},[],{"trials":5154,"activeCount":99},[],{"trials":5156,"activeCount":99},[],{"trials":5158,"activeCount":99},[],{"trials":5160,"activeCount":99},[5161,5165],{"nctId":4881,"briefTitle":4882,"status":123,"phases":5162,"primaryCompletion":3056,"completion":3056,"start":3117,"enrollment":16,"conditions":5163,"interventions":5164},[91],[15],[4841,4886],{"nctId":5166,"briefTitle":5167,"status":1322,"phases":5168,"primaryCompletion":5169,"completion":5169,"start":168,"enrollment":1123,"conditions":5170,"interventions":5171},"NCT00794313","Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease",[91],"2010-06",[15],[5172,5173,4886],"Amantadine 300 mg","Topiramate",{"intervention":5175,"totalTrials":132,"cells":5176},"Levodopa",{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5183,"PHASE4":5185,"NA":5187},{"trials":5178,"activeCount":99},[],{"trials":5180,"activeCount":99},[],{"trials":5182,"activeCount":99},[],{"trials":5184,"activeCount":99},[],{"trials":5186,"activeCount":99},[],{"trials":5188,"activeCount":99},[5189],{"nctId":5190,"briefTitle":5191,"status":2322,"phases":5192,"primaryCompletion":3511,"completion":3511,"start":166,"enrollment":99,"conditions":5193,"interventions":5194},"NCT01003002","Natural History of Levodopa-Induced Dyskinesia (LID)",[],[15],[5175],{"intervention":5196,"totalTrials":132,"cells":5197},"oral Valganciclovir vs oral Ganciclovir",{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5202,"PHASE3":5204,"PHASE4":5206,"NA":5208},{"trials":5199,"activeCount":99},[],{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":99},[],{"trials":5209,"activeCount":99},[5210],{"nctId":5211,"briefTitle":5212,"status":1555,"phases":5213,"completion":3393,"start":5214,"enrollment":1190,"conditions":5215,"interventions":5217},"NCT00364052","Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients",[],"2006-08",[5216],"Liver Transplantation",[5196],{"intervention":5219,"totalTrials":132,"cells":5220},"Pramlintide",{"EARLY_PHASE1":5221,"PHASE1":5223,"PHASE2":5225,"PHASE3":5227,"PHASE4":5229,"NA":5231},{"trials":5222,"activeCount":99},[],{"trials":5224,"activeCount":99},[],{"trials":5226,"activeCount":99},[],{"trials":5228,"activeCount":99},[],{"trials":5230,"activeCount":99},[],{"trials":5232,"activeCount":99},[5233],{"nctId":5234,"briefTitle":5235,"status":1555,"phases":5236,"primaryCompletion":5237,"completion":5237,"start":2643,"enrollment":1371,"conditions":5238,"interventions":5239},"NCT00691158","A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide",[91],"2024-07",[18],[5219,5240,5241],"2 Metreleptin","Leptin plus Pramlintide",{"intervention":5240,"totalTrials":132,"cells":5243},{"EARLY_PHASE1":5244,"PHASE1":5246,"PHASE2":5248,"PHASE3":5250,"PHASE4":5252,"NA":5254},{"trials":5245,"activeCount":99},[],{"trials":5247,"activeCount":99},[],{"trials":5249,"activeCount":99},[],{"trials":5251,"activeCount":99},[],{"trials":5253,"activeCount":99},[],{"trials":5255,"activeCount":99},[5256],{"nctId":5234,"briefTitle":5235,"status":1555,"phases":5257,"primaryCompletion":5237,"completion":5237,"start":2643,"enrollment":1371,"conditions":5258,"interventions":5259},[91],[18],[5219,5240,5241],{"intervention":5241,"totalTrials":132,"cells":5261},{"EARLY_PHASE1":5262,"PHASE1":5264,"PHASE2":5266,"PHASE3":5268,"PHASE4":5270,"NA":5272},{"trials":5263,"activeCount":99},[],{"trials":5265,"activeCount":99},[],{"trials":5267,"activeCount":99},[],{"trials":5269,"activeCount":99},[],{"trials":5271,"activeCount":99},[],{"trials":5273,"activeCount":99},[5274],{"nctId":5234,"briefTitle":5235,"status":1555,"phases":5275,"primaryCompletion":5237,"completion":5237,"start":2643,"enrollment":1371,"conditions":5276,"interventions":5277},[91],[18],[5219,5240,5241],{"intervention":5279,"totalTrials":132,"cells":5280},"Depo Lupron\u002FAromatase inhibitor",{"EARLY_PHASE1":5281,"PHASE1":5283,"PHASE2":5285,"PHASE3":5287,"PHASE4":5289,"NA":5291},{"trials":5282,"activeCount":99},[],{"trials":5284,"activeCount":99},[],{"trials":5286,"activeCount":99},[],{"trials":5288,"activeCount":99},[],{"trials":5290,"activeCount":99},[],{"trials":5292,"activeCount":99},[5293],{"nctId":5294,"briefTitle":5295,"status":1555,"phases":5296,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":116,"conditions":5300,"interventions":5302},"NCT00694733","Regulation of Cortisol Metabolism and Fat Patterning",[91],"2024-03","2024-09","2005-05",[18,5301],"Menopausal Syndrome",[5279,5303,5304],"Depo Lupron\u002Fplacebo","Estrogen cream",{"intervention":5303,"totalTrials":132,"cells":5306},{"EARLY_PHASE1":5307,"PHASE1":5309,"PHASE2":5311,"PHASE3":5313,"PHASE4":5315,"NA":5317},{"trials":5308,"activeCount":99},[],{"trials":5310,"activeCount":99},[],{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[],{"trials":5316,"activeCount":99},[],{"trials":5318,"activeCount":99},[5319],{"nctId":5294,"briefTitle":5295,"status":1555,"phases":5320,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":116,"conditions":5321,"interventions":5322},[91],[18,5301],[5279,5303,5304],{"intervention":5304,"totalTrials":132,"cells":5324},{"EARLY_PHASE1":5325,"PHASE1":5327,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5335},{"trials":5326,"activeCount":99},[],{"trials":5328,"activeCount":99},[],{"trials":5330,"activeCount":99},[],{"trials":5332,"activeCount":99},[],{"trials":5334,"activeCount":99},[],{"trials":5336,"activeCount":99},[5337],{"nctId":5294,"briefTitle":5295,"status":1555,"phases":5338,"primaryCompletion":5297,"completion":5298,"start":5299,"enrollment":116,"conditions":5339,"interventions":5340},[91],[18,5301],[5279,5303,5304],{"intervention":5342,"totalTrials":132,"cells":5343},"Hydrocortisone",{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5350,"PHASE4":5352,"NA":5354},{"trials":5345,"activeCount":99},[],{"trials":5347,"activeCount":99},[],{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":99},[],{"trials":5355,"activeCount":99},[5356],{"nctId":5357,"briefTitle":5358,"status":123,"phases":5359,"primaryCompletion":2849,"completion":4829,"start":5360,"enrollment":1098,"conditions":5361,"interventions":5363},"NCT00688987","The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation",[91],"2000-08",[18,5362],"Addison's Disease",[5342],{"intervention":5365,"totalTrials":132,"cells":5366},"Sunflower oil",{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5371,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5368,"activeCount":99},[],{"trials":5370,"activeCount":99},[],{"trials":5372,"activeCount":99},[],{"trials":5374,"activeCount":99},[],{"trials":5376,"activeCount":99},[],{"trials":5378,"activeCount":99},[5379],{"nctId":5380,"briefTitle":5381,"status":1555,"phases":5382,"primaryCompletion":167,"completion":5383,"start":1557,"enrollment":5384,"conditions":5385,"interventions":5387},"NCT01142999","Feasibility Study of Barrier Enhancement for Eczema Prevention",[91],"2012-09",46,[5386],"Eczema",[5365,5388,5389,5390],"Control group","Aquaphor ointment","Cetaphil cream",{"intervention":5388,"totalTrials":132,"cells":5392},{"EARLY_PHASE1":5393,"PHASE1":5395,"PHASE2":5397,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5394,"activeCount":99},[],{"trials":5396,"activeCount":99},[],{"trials":5398,"activeCount":99},[],{"trials":5400,"activeCount":99},[],{"trials":5402,"activeCount":99},[],{"trials":5404,"activeCount":99},[5405],{"nctId":5380,"briefTitle":5381,"status":1555,"phases":5406,"primaryCompletion":167,"completion":5383,"start":1557,"enrollment":5384,"conditions":5407,"interventions":5408},[91],[5386],[5365,5388,5389,5390],{"intervention":5389,"totalTrials":132,"cells":5410},{"EARLY_PHASE1":5411,"PHASE1":5413,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[],{"trials":5418,"activeCount":99},[],{"trials":5420,"activeCount":99},[],{"trials":5422,"activeCount":99},[5423],{"nctId":5380,"briefTitle":5381,"status":1555,"phases":5424,"primaryCompletion":167,"completion":5383,"start":1557,"enrollment":5384,"conditions":5425,"interventions":5426},[91],[5386],[5365,5388,5389,5390],{"intervention":5390,"totalTrials":132,"cells":5428},{"EARLY_PHASE1":5429,"PHASE1":5431,"PHASE2":5433,"PHASE3":5435,"PHASE4":5437,"NA":5439},{"trials":5430,"activeCount":99},[],{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"trials":5438,"activeCount":99},[],{"trials":5440,"activeCount":99},[5441],{"nctId":5380,"briefTitle":5381,"status":1555,"phases":5442,"primaryCompletion":167,"completion":5383,"start":1557,"enrollment":5384,"conditions":5443,"interventions":5444},[91],[5386],[5365,5388,5389,5390],{"intervention":5446,"totalTrials":132,"cells":5447},"Octreotide",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5452,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5449,"activeCount":99},[],{"trials":5451,"activeCount":99},[],{"trials":5453,"activeCount":99},[],{"trials":5455,"activeCount":99},[],{"trials":5457,"activeCount":99},[],{"trials":5459,"activeCount":99},[5460],{"nctId":5461,"briefTitle":5462,"status":1555,"phases":5463,"primaryCompletion":5297,"completion":2213,"start":5464,"enrollment":95,"conditions":5465,"interventions":5467},"NCT01613495","Ghrelin Suppression by Octreotide in Prader-Willi",[91],"2005-08",[5466],"Prader Willis Syndrome",[5446],{"intervention":5469,"totalTrials":132,"cells":5470},"Misoprostol",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5477,"PHASE4":5479,"NA":5481},{"trials":5472,"activeCount":99},[],{"trials":5474,"activeCount":99},[],{"trials":5476,"activeCount":99},[],{"trials":5478,"activeCount":99},[],{"trials":5480,"activeCount":99},[],{"trials":5482,"activeCount":99},[5483],{"nctId":5484,"briefTitle":5485,"status":123,"phases":5486,"primaryCompletion":1298,"completion":166,"start":5487,"enrollment":467,"conditions":5488,"interventions":5489},"NCT00613366","Misoprostol With Intrauterine Device Insertion",[91],"2007-06",[24],[5469],{"intervention":5491,"totalTrials":132,"cells":5492},"Insertion of nitroglycerin ointment",{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5499,"PHASE4":5501,"NA":5503},{"trials":5494,"activeCount":99},[],{"trials":5496,"activeCount":99},[],{"trials":5498,"activeCount":99},[],{"trials":5500,"activeCount":99},[],{"trials":5502,"activeCount":99},[],{"trials":5504,"activeCount":99},[5505],{"nctId":5506,"briefTitle":5507,"status":123,"phases":5508,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1098,"conditions":5511,"interventions":5512},"NCT01490073","The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women",[91],"2012-11-01","2012-03-01",[24,27],[5491,5513],"Insertion of placebo ointment",{"intervention":5513,"totalTrials":132,"cells":5515},{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5517,"activeCount":99},[],{"trials":5519,"activeCount":99},[],{"trials":5521,"activeCount":99},[],{"trials":5523,"activeCount":99},[],{"trials":5525,"activeCount":99},[],{"trials":5527,"activeCount":99},[5528],{"nctId":5506,"briefTitle":5507,"status":123,"phases":5529,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":1098,"conditions":5530,"interventions":5531},[91],[24,27],[5491,5513],{"intervention":5533,"totalTrials":132,"cells":5534},"Cabotegravir",{"EARLY_PHASE1":5535,"PHASE1":5537,"PHASE2":5539,"PHASE3":5541,"PHASE4":5543,"NA":5545},{"trials":5536,"activeCount":99},[],{"trials":5538,"activeCount":99},[],{"trials":5540,"activeCount":99},[],{"trials":5542,"activeCount":99},[],{"trials":5544,"activeCount":99},[],{"trials":5546,"activeCount":99},[5547],{"nctId":5548,"briefTitle":5549,"status":1555,"phases":5550,"primaryCompletion":5551,"completion":5551,"start":5552,"enrollment":5553,"conditions":5554,"interventions":5556},"NCT05949203","Oregon PrEP at Home Study",[],"2025-12-01","2023-12-01",125,[5555],"HIV\u002FAIDS",[5533],{"intervention":5558,"totalTrials":132,"cells":5559},"Intralipid\u002FHeparin",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5564,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5561,"activeCount":99},[],{"trials":5563,"activeCount":99},[],{"trials":5565,"activeCount":99},[],{"trials":5567,"activeCount":99},[],{"trials":5569,"activeCount":99},[],{"trials":5571,"activeCount":99},[5572],{"nctId":5573,"briefTitle":5574,"status":123,"phases":5575,"primaryCompletion":5576,"completion":3367,"start":3343,"enrollment":1300,"conditions":5577,"interventions":5584},"NCT02517307","Fatty Acid Oxidation Defects and Insulin Sensitivity",[91],"2021-01",[5578,5579,5580,5581,5582,5583],"Very Long-chain Acyl-CoA Dehydrogenase Deficiency","Trifunctional Protein Deficiency","Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency","Medium-chain Acyl-CoA Dehydrogenase Deficiency","Normal Volunteers","Carnitine Palmitoyltransferase II Deficiency, Myopathic",[5558,5585,5586],"Glycerol\u002FSaline","Hyperinsulinemic euglycemic clamp",{"intervention":5585,"totalTrials":132,"cells":5588},{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5595,"PHASE4":5597,"NA":5599},{"trials":5590,"activeCount":99},[],{"trials":5592,"activeCount":99},[],{"trials":5594,"activeCount":99},[],{"trials":5596,"activeCount":99},[],{"trials":5598,"activeCount":99},[],{"trials":5600,"activeCount":99},[5601],{"nctId":5573,"briefTitle":5574,"status":123,"phases":5602,"primaryCompletion":5576,"completion":3367,"start":3343,"enrollment":1300,"conditions":5603,"interventions":5604},[91],[5578,5579,5580,5581,5582,5583],[5558,5585,5586],{"intervention":5586,"totalTrials":132,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5613,"PHASE4":5615,"NA":5617},{"trials":5608,"activeCount":99},[],{"trials":5610,"activeCount":99},[],{"trials":5612,"activeCount":99},[],{"trials":5614,"activeCount":99},[],{"trials":5616,"activeCount":99},[],{"trials":5618,"activeCount":99},[5619],{"nctId":5573,"briefTitle":5574,"status":123,"phases":5620,"primaryCompletion":5576,"completion":3367,"start":3343,"enrollment":1300,"conditions":5621,"interventions":5622},[91],[5578,5579,5580,5581,5582,5583],[5558,5585,5586],{"intervention":5624,"totalTrials":132,"cells":5625},"Enoxaparin dose adjusted Lovenox based on TEG",{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5630,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5627,"activeCount":99},[],{"trials":5629,"activeCount":99},[],{"trials":5631,"activeCount":99},[],{"trials":5633,"activeCount":99},[],{"trials":5635,"activeCount":99},[],{"trials":5637,"activeCount":99},[5638],{"nctId":5639,"briefTitle":5640,"status":123,"phases":5641,"primaryCompletion":5101,"completion":5101,"start":168,"enrollment":5642,"conditions":5643,"interventions":5645},"NCT00990236","Thrombelastography Based Dosing of Enoxaparin",[91],185,[5644],"Thromboembolic Complications",[5624,5646],"Enoxaparin 30 mg BID",{"intervention":5646,"totalTrials":132,"cells":5648},{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5653,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5650,"activeCount":99},[],{"trials":5652,"activeCount":99},[],{"trials":5654,"activeCount":99},[],{"trials":5656,"activeCount":99},[],{"trials":5658,"activeCount":99},[],{"trials":5660,"activeCount":99},[5661],{"nctId":5639,"briefTitle":5640,"status":123,"phases":5662,"primaryCompletion":5101,"completion":5101,"start":168,"enrollment":5642,"conditions":5663,"interventions":5664},[91],[5644],[5624,5646],{"intervention":5666,"totalTrials":132,"cells":5667},"Infliximab",{"EARLY_PHASE1":5668,"PHASE1":5670,"PHASE2":5672,"PHASE3":5674,"PHASE4":5676,"NA":5678},{"trials":5669,"activeCount":99},[],{"trials":5671,"activeCount":99},[],{"trials":5673,"activeCount":99},[],{"trials":5675,"activeCount":99},[],{"trials":5677,"activeCount":99},[],{"trials":5679,"activeCount":99},[5680],{"nctId":5681,"briefTitle":5682,"status":2322,"phases":5683,"primaryCompletion":4875,"completion":4875,"start":166,"enrollment":99,"conditions":5684,"interventions":5686},"NCT01266785","Infliximab, Regulatory T Cells, IL2 and Crohn's Disease",[91],[5685],"Crohn's Disease",[5666],{"intervention":5688,"totalTrials":132,"cells":5689},"oral corticosteroid taper",{"EARLY_PHASE1":5690,"PHASE1":5692,"PHASE2":5694,"PHASE3":5696,"PHASE4":5698,"NA":5700},{"trials":5691,"activeCount":99},[],{"trials":5693,"activeCount":99},[],{"trials":5695,"activeCount":99},[],{"trials":5697,"activeCount":99},[],{"trials":5699,"activeCount":99},[],{"trials":5701,"activeCount":99},[5702],{"nctId":5703,"briefTitle":5704,"status":2322,"phases":5705,"primaryCompletion":5706,"completion":5706,"start":166,"enrollment":99,"conditions":5707,"interventions":5709},"NCT01255683","Oral Steroid Treatment for Chronic Rhinosinusitis",[],"2011-11",[5708],"Chronic Rhinosinusitis",[5688],{"intervention":5711,"totalTrials":132,"cells":5712},"Hydrochlorothiazide",{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5719,"PHASE4":5721,"NA":5723},{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[],{"trials":5718,"activeCount":99},[],{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[],{"trials":5724,"activeCount":99},[5725],{"nctId":5726,"briefTitle":5727,"status":123,"phases":5728,"primaryCompletion":1890,"completion":3183,"start":2485,"enrollment":1936,"conditions":5729,"interventions":5731},"NCT00822107","A Translational Approach to Gitelman Syndrome",[91],[5730],"Gitelman Syndrome",[5711],{"intervention":5733,"totalTrials":132,"cells":5734},"Niclosamide",{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5739,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5736,"activeCount":99},[],{"trials":5738,"activeCount":99},[],{"trials":5740,"activeCount":99},[],{"trials":5742,"activeCount":99},[],{"trials":5744,"activeCount":99},[],{"trials":5746,"activeCount":99},[5747],{"nctId":5748,"briefTitle":5749,"status":123,"phases":5750,"primaryCompletion":1890,"completion":1890,"start":3232,"enrollment":5751,"conditions":5752,"interventions":5754},"NCT01296958","Targeted Screening for Taenia Solium Tapeworms",[91],1811,[5753],"Taenia Solium Taeniasis",[5733],{"intervention":5756,"totalTrials":132,"cells":5757},"Norditropin",{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5762,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5759,"activeCount":99},[],{"trials":5761,"activeCount":99},[],{"trials":5763,"activeCount":99},[],{"trials":5765,"activeCount":99},[],{"trials":5767,"activeCount":99},[],{"trials":5769,"activeCount":99},[5770],{"nctId":5771,"briefTitle":5772,"status":2322,"phases":5773,"primaryCompletion":4719,"completion":4055,"start":5774,"enrollment":99,"conditions":5775,"interventions":5777},"NCT00720616","Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.",[91],"2010-10",[5776],"Metabolic Syndrome",[5756],{"intervention":5779,"totalTrials":132,"cells":5780},"Intrauterine lidocaine infusion 4%",{"EARLY_PHASE1":5781,"PHASE1":5783,"PHASE2":5785,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5782,"activeCount":99},[],{"trials":5784,"activeCount":99},[],{"trials":5786,"activeCount":99},[],{"trials":5788,"activeCount":99},[],{"trials":5790,"activeCount":99},[],{"trials":5792,"activeCount":99},[5793],{"nctId":5794,"briefTitle":5795,"status":123,"phases":5796,"completion":5797,"enrollment":927,"conditions":5798,"interventions":5799},"NCT00121329","4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions",[91],"2004-12",[27],[5779],{"intervention":5801,"totalTrials":132,"cells":5802},"Desogen",{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5807,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5804,"activeCount":99},[],{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[],{"trials":5810,"activeCount":99},[],{"trials":5812,"activeCount":99},[],{"trials":5814,"activeCount":99},[5815],{"nctId":5816,"briefTitle":5817,"status":123,"phases":5818,"primaryCompletion":2145,"completion":2145,"start":2368,"enrollment":9,"conditions":5819,"interventions":5821},"NCT00612508","Hormonal Contraception and Vaginal Health",[91],[118,5820],"Vaginal Epithelial Disruption",[5801,5822],"NuvaRing",{"intervention":5822,"totalTrials":132,"cells":5824},{"EARLY_PHASE1":5825,"PHASE1":5827,"PHASE2":5829,"PHASE3":5831,"PHASE4":5833,"NA":5835},{"trials":5826,"activeCount":99},[],{"trials":5828,"activeCount":99},[],{"trials":5830,"activeCount":99},[],{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[],{"trials":5836,"activeCount":99},[5837],{"nctId":5816,"briefTitle":5817,"status":123,"phases":5838,"primaryCompletion":2145,"completion":2145,"start":2368,"enrollment":9,"conditions":5839,"interventions":5840},[91],[118,5820],[5801,5822],{"intervention":5842,"totalTrials":132,"cells":5843},"Nutropin",{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5850,"PHASE4":5852,"NA":5854},{"trials":5845,"activeCount":99},[],{"trials":5847,"activeCount":99},[],{"trials":5849,"activeCount":99},[],{"trials":5851,"activeCount":99},[],{"trials":5853,"activeCount":99},[],{"trials":5855,"activeCount":99},[5856],{"nctId":5857,"briefTitle":5858,"status":2322,"phases":5859,"primaryCompletion":1754,"completion":1754,"start":5774,"enrollment":99,"conditions":5860,"interventions":5861},"NCT00518635","Low Dose Growth Hormone in Obese PCOS Women",[91],[5058],[5842],{"intervention":4973,"totalTrials":132,"cells":5863},{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5868,"PHASE3":5870,"PHASE4":5872,"NA":5874},{"trials":5865,"activeCount":99},[],{"trials":5867,"activeCount":99},[],{"trials":5869,"activeCount":99},[],{"trials":5871,"activeCount":99},[],{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[5876],{"nctId":4966,"briefTitle":4967,"status":123,"phases":5877,"primaryCompletion":4812,"completion":1890,"start":4969,"enrollment":1779,"conditions":5878,"interventions":5879},[91],[4971],[4973,4974,4975,4976],{"intervention":4975,"totalTrials":132,"cells":5881},{"EARLY_PHASE1":5882,"PHASE1":5884,"PHASE2":5886,"PHASE3":5888,"PHASE4":5890,"NA":5892},{"trials":5883,"activeCount":99},[],{"trials":5885,"activeCount":99},[],{"trials":5887,"activeCount":99},[],{"trials":5889,"activeCount":99},[],{"trials":5891,"activeCount":99},[],{"trials":5893,"activeCount":99},[5894],{"nctId":4966,"briefTitle":4967,"status":123,"phases":5895,"primaryCompletion":4812,"completion":1890,"start":4969,"enrollment":1779,"conditions":5896,"interventions":5897},[91],[4971],[4973,4974,4975,4976],{"intervention":4976,"totalTrials":132,"cells":5899},{"EARLY_PHASE1":5900,"PHASE1":5902,"PHASE2":5904,"PHASE3":5906,"PHASE4":5908,"NA":5910},{"trials":5901,"activeCount":99},[],{"trials":5903,"activeCount":99},[],{"trials":5905,"activeCount":99},[],{"trials":5907,"activeCount":99},[],{"trials":5909,"activeCount":99},[],{"trials":5911,"activeCount":99},[5912],{"nctId":4966,"briefTitle":4967,"status":123,"phases":5913,"primaryCompletion":4812,"completion":1890,"start":4969,"enrollment":1779,"conditions":5914,"interventions":5915},[91],[4971],[4973,4974,4975,4976],{"intervention":5917,"totalTrials":132,"cells":5918},"Dietary supplement for weight loss",{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5925,"PHASE4":5927,"NA":5929},{"trials":5920,"activeCount":99},[],{"trials":5922,"activeCount":99},[],{"trials":5924,"activeCount":99},[],{"trials":5926,"activeCount":99},[],{"trials":5928,"activeCount":99},[],{"trials":5930,"activeCount":99},[5931],{"nctId":5932,"briefTitle":5933,"status":123,"phases":5934,"primaryCompletion":5487,"completion":2390,"start":2047,"enrollment":2281,"conditions":5935,"interventions":5939},"NCT00129792","Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome",[91],[5936,5937,5050,18,5938],"Metabolic Syndrome X","Prediabetic State","Metabolic Diseases",[5917],{"intervention":5941,"totalTrials":132,"cells":5942},"betamethasone",{"EARLY_PHASE1":5943,"PHASE1":5945,"PHASE2":5947,"PHASE3":5949,"PHASE4":5951,"NA":5953},{"trials":5944,"activeCount":99},[],{"trials":5946,"activeCount":99},[],{"trials":5948,"activeCount":99},[],{"trials":5950,"activeCount":99},[],{"trials":5952,"activeCount":99},[],{"trials":5954,"activeCount":99},[5955],{"nctId":5956,"briefTitle":5957,"status":123,"phases":5958,"primaryCompletion":5959,"completion":3081,"start":5960,"enrollment":5961,"conditions":5962,"interventions":5966},"NCT00669383","Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants",[91],"2007-07","2001-06",85,[5963,5964,5965],"Respiratory Compliance","Functional Residual Capacity","Pulmonary Function Testing",[5941],{"intervention":5968,"totalTrials":132,"cells":5969},"inhaled corticosteroid therapy",{"EARLY_PHASE1":5970,"PHASE1":5972,"PHASE2":5974,"PHASE3":5976,"PHASE4":5978,"NA":5980},{"trials":5971,"activeCount":99},[],{"trials":5973,"activeCount":99},[],{"trials":5975,"activeCount":99},[],{"trials":5977,"activeCount":99},[],{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[5982],{"nctId":5983,"briefTitle":5984,"status":123,"phases":5985,"primaryCompletion":5986,"completion":3982,"start":5987,"enrollment":5988,"conditions":5989,"interventions":5991},"NCT02714283","Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis",[],"2018-06-30","2016-10-28",90089,[5990],"Bronchiectasis",[5968,5992],"macrolide therapy",{"intervention":5992,"totalTrials":132,"cells":5994},{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[],{"trials":6000,"activeCount":99},[],{"trials":6002,"activeCount":99},[],{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":99},[6007],{"nctId":5983,"briefTitle":5984,"status":123,"phases":6008,"primaryCompletion":5986,"completion":3982,"start":5987,"enrollment":5988,"conditions":6009,"interventions":6010},[],[5990],[5968,5992],{"intervention":6012,"totalTrials":132,"cells":6013},"Remicade",{"EARLY_PHASE1":6014,"PHASE1":6016,"PHASE2":6018,"PHASE3":6020,"PHASE4":6022,"NA":6024},{"trials":6015,"activeCount":99},[],{"trials":6017,"activeCount":99},[],{"trials":6019,"activeCount":99},[],{"trials":6021,"activeCount":99},[],{"trials":6023,"activeCount":99},[],{"trials":6025,"activeCount":99},[6026],{"nctId":6027,"briefTitle":6028,"status":123,"phases":6029,"primaryCompletion":6030,"completion":6030,"start":6031,"enrollment":1986,"conditions":6032,"interventions":6033},"NCT00273390","A Clinical Trial of Infliximab for Uveitis",[91],"2006-12","2001-08",[2761],[6012],{"intervention":6035,"totalTrials":132,"cells":6036},"Echo and myocardial contrast echocardiography perfusion imaging",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6041,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6038,"activeCount":99},[],{"trials":6040,"activeCount":99},[],{"trials":6042,"activeCount":99},[],{"trials":6044,"activeCount":99},[],{"trials":6046,"activeCount":99},[],{"trials":6048,"activeCount":99},[6049],{"nctId":6050,"briefTitle":6051,"status":1555,"phases":6052,"primaryCompletion":6053,"completion":6054,"start":6055,"enrollment":1371,"conditions":6056,"interventions":6058},"NCT02560467","Perfusion Imaging With Myocardial Contrast Echocardiography in HCM",[91],"2019-09-01","2019-09-15","2015-12-01",[6057],"Hypertrophic Cardiomyopathy",[6035],{"intervention":6060,"totalTrials":132,"cells":6061},"Lybrel",{"EARLY_PHASE1":6062,"PHASE1":6064,"PHASE2":6066,"PHASE3":6068,"PHASE4":6070,"NA":6072},{"trials":6063,"activeCount":99},[],{"trials":6065,"activeCount":99},[],{"trials":6067,"activeCount":99},[],{"trials":6069,"activeCount":99},[],{"trials":6071,"activeCount":99},[],{"trials":6073,"activeCount":99},[6074],{"nctId":6075,"briefTitle":6076,"status":123,"phases":6077,"primaryCompletion":2483,"completion":3232,"start":2368,"enrollment":6078,"conditions":6079,"interventions":6081},"NCT00480532","A Study of Continuous Oral Contraceptives and Doxycycline",[91],131,[6080],"Contraceptives, Oral",[6060,6082,6083,6084,6085],"Doxycycline","Oracea","Doxycycline 100bid x5 days at the time of bleeding","Subantimicrobial doxycycline daily",{"intervention":6082,"totalTrials":132,"cells":6087},{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6094,"PHASE4":6096,"NA":6098},{"trials":6089,"activeCount":99},[],{"trials":6091,"activeCount":99},[],{"trials":6093,"activeCount":99},[],{"trials":6095,"activeCount":99},[],{"trials":6097,"activeCount":99},[],{"trials":6099,"activeCount":99},[6100],{"nctId":6075,"briefTitle":6076,"status":123,"phases":6101,"primaryCompletion":2483,"completion":3232,"start":2368,"enrollment":6078,"conditions":6102,"interventions":6103},[91],[6080],[6060,6082,6083,6084,6085],{"intervention":6083,"totalTrials":132,"cells":6105},{"EARLY_PHASE1":6106,"PHASE1":6108,"PHASE2":6110,"PHASE3":6112,"PHASE4":6114,"NA":6116},{"trials":6107,"activeCount":99},[],{"trials":6109,"activeCount":99},[],{"trials":6111,"activeCount":99},[],{"trials":6113,"activeCount":99},[],{"trials":6115,"activeCount":99},[],{"trials":6117,"activeCount":99},[6118],{"nctId":6075,"briefTitle":6076,"status":123,"phases":6119,"primaryCompletion":2483,"completion":3232,"start":2368,"enrollment":6078,"conditions":6120,"interventions":6121},[91],[6080],[6060,6082,6083,6084,6085],{"intervention":6084,"totalTrials":132,"cells":6123},{"EARLY_PHASE1":6124,"PHASE1":6126,"PHASE2":6128,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6125,"activeCount":99},[],{"trials":6127,"activeCount":99},[],{"trials":6129,"activeCount":99},[],{"trials":6131,"activeCount":99},[],{"trials":6133,"activeCount":99},[],{"trials":6135,"activeCount":99},[6136],{"nctId":6075,"briefTitle":6076,"status":123,"phases":6137,"primaryCompletion":2483,"completion":3232,"start":2368,"enrollment":6078,"conditions":6138,"interventions":6139},[91],[6080],[6060,6082,6083,6084,6085],{"intervention":6085,"totalTrials":132,"cells":6141},{"EARLY_PHASE1":6142,"PHASE1":6144,"PHASE2":6146,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6143,"activeCount":99},[],{"trials":6145,"activeCount":99},[],{"trials":6147,"activeCount":99},[],{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":99},[6154],{"nctId":6075,"briefTitle":6076,"status":123,"phases":6155,"primaryCompletion":2483,"completion":3232,"start":2368,"enrollment":6078,"conditions":6156,"interventions":6157},[91],[6080],[6060,6082,6083,6084,6085],{"intervention":6159,"totalTrials":132,"cells":6160},"Pegvisomant",{"EARLY_PHASE1":6161,"PHASE1":6163,"PHASE2":6165,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6162,"activeCount":99},[],{"trials":6164,"activeCount":99},[],{"trials":6166,"activeCount":99},[],{"trials":6168,"activeCount":99},[],{"trials":6170,"activeCount":99},[],{"trials":6172,"activeCount":99},[6173],{"nctId":6174,"briefTitle":6175,"status":1555,"phases":6176,"primaryCompletion":2238,"completion":2098,"start":1984,"enrollment":1371,"conditions":6177,"interventions":6179},"NCT01804413","Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency",[91],[6178],"Adults Growth Hormone Deficiency.",[6159,6180],"Regular insulin",{"intervention":6180,"totalTrials":132,"cells":6182},{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6187,"PHASE3":6189,"PHASE4":6191,"NA":6193},{"trials":6184,"activeCount":99},[],{"trials":6186,"activeCount":99},[],{"trials":6188,"activeCount":99},[],{"trials":6190,"activeCount":99},[],{"trials":6192,"activeCount":99},[],{"trials":6194,"activeCount":99},[6195],{"nctId":6174,"briefTitle":6175,"status":1555,"phases":6196,"primaryCompletion":2238,"completion":2098,"start":1984,"enrollment":1371,"conditions":6197,"interventions":6198},[91],[6178],[6159,6180],{"intervention":6200,"totalTrials":132,"cells":6201},"Birth control pills",{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6208,"PHASE4":6210,"NA":6212},{"trials":6203,"activeCount":99},[],{"trials":6205,"activeCount":99},[],{"trials":6207,"activeCount":99},[],{"trials":6209,"activeCount":99},[],{"trials":6211,"activeCount":99},[],{"trials":6213,"activeCount":99},[6214],{"nctId":6215,"briefTitle":6216,"status":123,"phases":6217,"completion":4829,"enrollment":169,"conditions":6218,"interventions":6219},"NCT00120913","Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?",[91],[1167],[6200],{"intervention":6221,"totalTrials":132,"cells":6222},"Dimethyl fumarate",{"EARLY_PHASE1":6223,"PHASE1":6225,"PHASE2":6227,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6224,"activeCount":99},[],{"trials":6226,"activeCount":99},[],{"trials":6228,"activeCount":99},[],{"trials":6230,"activeCount":99},[],{"trials":6232,"activeCount":99},[],{"trials":6234,"activeCount":99},[6235],{"nctId":6236,"briefTitle":6237,"status":1322,"phases":6238,"primaryCompletion":6239,"completion":6239,"start":3343,"enrollment":1326,"conditions":6240,"interventions":6241},"NCT02644083","Tecfidera and MRI for Brain Energy in MS",[],"2018-07",[21],[6221],{"intervention":6243,"totalTrials":132,"cells":6244},"Mineral Trioxide Aggregate",{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6251,"PHASE4":6253,"NA":6255},{"trials":6246,"activeCount":99},[],{"trials":6248,"activeCount":99},[],{"trials":6250,"activeCount":99},[],{"trials":6252,"activeCount":99},[],{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[6257],{"nctId":6258,"briefTitle":6259,"status":123,"phases":6260,"primaryCompletion":1846,"completion":1846,"start":1558,"enrollment":6261,"conditions":6262,"interventions":6264},"NCT00812877","Pulp Capping With Two Different Agents",[91],376,[6263],"Dental Pulp Exposure",[6243,6265],"Calcium Hydroxide",{"intervention":6265,"totalTrials":132,"cells":6267},{"EARLY_PHASE1":6268,"PHASE1":6270,"PHASE2":6272,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6269,"activeCount":99},[],{"trials":6271,"activeCount":99},[],{"trials":6273,"activeCount":99},[],{"trials":6275,"activeCount":99},[],{"trials":6277,"activeCount":99},[],{"trials":6279,"activeCount":99},[6280],{"nctId":6258,"briefTitle":6259,"status":123,"phases":6281,"primaryCompletion":1846,"completion":1846,"start":1558,"enrollment":6261,"conditions":6282,"interventions":6283},[91],[6263],[6243,6265],{"intervention":6285,"totalTrials":132,"cells":6286},"RBC units",{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6291,"PHASE3":6293,"PHASE4":6295,"NA":6297},{"trials":6288,"activeCount":99},[],{"trials":6290,"activeCount":99},[],{"trials":6292,"activeCount":99},[],{"trials":6294,"activeCount":99},[],{"trials":6296,"activeCount":99},[],{"trials":6298,"activeCount":99},[6299],{"nctId":6300,"briefTitle":6301,"status":123,"phases":6302,"primaryCompletion":3513,"completion":3513,"start":2483,"enrollment":6303,"conditions":6304,"interventions":6306},"NCT01038557","Frozen Red Blood Cell Transfusions in Trauma Patients",[91],254,[171,6305,2513],"Anemia",[6285],{"intervention":6308,"totalTrials":132,"cells":6309},"Supplemental metolazone diuresis",{"EARLY_PHASE1":6310,"PHASE1":6312,"PHASE2":6314,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6311,"activeCount":99},[],{"trials":6313,"activeCount":99},[],{"trials":6315,"activeCount":99},[],{"trials":6317,"activeCount":99},[],{"trials":6319,"activeCount":99},[],{"trials":6321,"activeCount":99},[6322],{"nctId":6323,"briefTitle":6324,"status":2322,"phases":6325,"primaryCompletion":6326,"completion":6326,"start":4812,"enrollment":99,"conditions":6327,"interventions":6331},"NCT01617798","Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis",[91],"2013-06",[6328,6329,6330],"Respiratory Failure","Volume Overload","Hypernatremia",[6308],{"intervention":5172,"totalTrials":132,"cells":6333},{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6340,"PHASE4":6342,"NA":6344},{"trials":6335,"activeCount":99},[],{"trials":6337,"activeCount":99},[],{"trials":6339,"activeCount":99},[],{"trials":6341,"activeCount":99},[],{"trials":6343,"activeCount":99},[],{"trials":6345,"activeCount":99},[6346],{"nctId":5166,"briefTitle":5167,"status":1322,"phases":6347,"primaryCompletion":5169,"completion":5169,"start":168,"enrollment":1123,"conditions":6348,"interventions":6349},[91],[15],[5172,5173,4886],{"intervention":5173,"totalTrials":132,"cells":6351},{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6356,"PHASE3":6358,"PHASE4":6360,"NA":6362},{"trials":6353,"activeCount":99},[],{"trials":6355,"activeCount":99},[],{"trials":6357,"activeCount":99},[],{"trials":6359,"activeCount":99},[],{"trials":6361,"activeCount":99},[],{"trials":6363,"activeCount":99},[6364],{"nctId":5166,"briefTitle":5167,"status":1322,"phases":6365,"primaryCompletion":5169,"completion":5169,"start":168,"enrollment":1123,"conditions":6366,"interventions":6367},[91],[15],[5172,5173,4886],{"intervention":6369,"totalTrials":132,"cells":6370},"Vancomycin",{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6375,"PHASE3":6377,"PHASE4":6379,"NA":6381},{"trials":6372,"activeCount":99},[],{"trials":6374,"activeCount":99},[],{"trials":6376,"activeCount":99},[],{"trials":6378,"activeCount":99},[],{"trials":6380,"activeCount":99},[],{"trials":6382,"activeCount":99},[6383],{"nctId":6384,"briefTitle":6385,"status":123,"phases":6386,"primaryCompletion":6387,"completion":6387,"start":6388,"enrollment":6389,"conditions":6390,"interventions":6392},"NCT00915967","Prevention of Neurosurgical Wound Infections",[91],"2014-12-19","2009-05-13",214,[6391],"Surgical Wound Infections",[6369],{"intervention":6394,"totalTrials":132,"cells":6395},"3,4-diaminopyridine",{"EARLY_PHASE1":6396,"PHASE1":6398,"PHASE2":6400,"PHASE3":6402,"PHASE4":6404,"NA":6406},{"trials":6397,"activeCount":99},[],{"trials":6399,"activeCount":99},[],{"trials":6401,"activeCount":99},[],{"trials":6403,"activeCount":99},[],{"trials":6405,"activeCount":99},[],{"trials":6407,"activeCount":99},[6408],{"nctId":6409,"briefTitle":6410,"status":6411,"phases":6412,"conditions":6413,"interventions":6416},"NCT02012933","3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)","NO_LONGER_AVAILABLE",[],[6414,6415],"Lambert-Eaton Myasthenic Syndrome (LEMS)","Congenital Myasthenia (CM)",[6394],{"intervention":6418,"totalTrials":132,"cells":6419},"Bortezomib",{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6426,"PHASE4":6428,"NA":6430},{"trials":6421,"activeCount":99},[],{"trials":6423,"activeCount":99},[],{"trials":6425,"activeCount":99},[],{"trials":6427,"activeCount":99},[],{"trials":6429,"activeCount":99},[],{"trials":6431,"activeCount":99},[6432],{"nctId":6433,"briefTitle":6434,"status":123,"phases":6435,"primaryCompletion":6436,"completion":1413,"start":6437,"enrollment":34,"conditions":6438,"interventions":6442},"NCT02026505","Evaluation of Cardiotoxic Effects of Bortezomib",[],"2016-12-31","2014-03-01",[6439,6440,6441],"Multiple Myeloma","Heart Failure, Systolic","Cardiotoxins",[6418]]